CN1733304A - Anticancer medicine composition containing blood vessel inhibitor - Google Patents
Anticancer medicine composition containing blood vessel inhibitor Download PDFInfo
- Publication number
- CN1733304A CN1733304A CN 200510044381 CN200510044381A CN1733304A CN 1733304 A CN1733304 A CN 1733304A CN 200510044381 CN200510044381 CN 200510044381 CN 200510044381 A CN200510044381 A CN 200510044381A CN 1733304 A CN1733304 A CN 1733304A
- Authority
- CN
- China
- Prior art keywords
- dihydro
- methylene
- dihydroindole ketone
- methyl
- indole
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
Disclosed is an anti-cancer medicine composition which comprises anti-cancer active constituent and medicinal adjuvant, wherein the active anti-cancer constituents mainly include blood vessel depressant and anti-cancer medicament, the anti-cancer medicament is selected from diclo ethylamine drugs, paclitaxels anti-cancer drugs, anti-cancer antibiotic drugs and/or antimetabolites. The medicinal subsidiary materials mainly comprise bio-compactable and degradable macromolecular polymers, which can slowly release the anti-cancer medicament onto tumor partially during the degradation and absorption process, thus the whole body toxicity reaction is reduced appreciably, and the effective medicinal concentration can be sustained to the tumor partially. The composition can lower down the whole body toxicity reaction of the medicament when locally dispensing on the tumor, selectively increase the tumor local medicinal concentration, and the treatment effect of the non-operative treatment methods such as chemotherapy, medicament and radiation can be improved.
Description
(1) technical field
The present invention relates to a kind of anticancer pharmaceutical composition, belong to technical field of pharmaceuticals.
(2) background technology
Treatment for cancer mainly comprises methods such as operation, radiotherapy and chemotherapy.Therefore wherein operative treatment not only can not be known the oncocyte that is dispersed in, and often recurs or causes tumor cell to stimulate diffusion transfer because of operation; Radiotherapy and traditional chemotherapy are not had a selectivity, and be difficult to tumor by local and form effective drug level or therapeutic dose, weak effect, toxicity is big, improves the restriction that medicine or radiological dose are subjected to general toxic reaction again merely.Referring to " placing cisplatin adding system carmustine treatment rat brain tumor in the tumor " " surgery tumor magazine " 69 phase 76-82 pages or leaves (1998) (Kong Q et al., J Surg Oncol.1998 Oct such as Kong Qingzhongs; 69 (2): 76-82).
The local placement of antitumor drug can overcome above defective preferably, not only can obviously improve the drug level of tumor by local, and can significantly reduce general toxic reaction.A large amount of internal and external tests have demonstrated the therapeutic effect to entity tumor, referring to " placing cisplatin adding system carmustine treatment rat brain tumor in the tumor " " surgery tumor magazine " 69 phase 76-82 pages or leaves (1998) (Kong Q et al., J Surg Oncol.1998 Oct such as Kong Qingzhongs; 69 (2): 76-82) and Kong Qingzhong etc. " place cisplatin in the tumor and cure the former carbuncle in the occipital region tumor of rat " " surgery tumor magazine " 64 phase 268-273 pages or leaves (1997) (Kong Q et al., J Surg Oncol.1997 Oct; 64:268-273).Also can be referring to referring to Chinese patent (ZL00111093.4; ZL96115937.5; Application number 001111264,001111272) and U.S.'s patent of invention (patent No. 6,376,525B1; 5,651,986; 5,626,862).
Yet, entity tumor is made up of tumor cell and mesenchyma stroma of tumors, wherein the blood vessel in the mesenchyma stroma of tumors not only provides support and requisite nutrient substance for the growth of tumor cell, also influenced chemotherapeutics around tumor and the infiltration in the tumor tissues and diffusion (carry and to wait " situation of extracellular matrix to entity tumor in the medicine influence of turning round " " cancer research " 60 phase 2497-503 page or leaf (2000) (Netti PA referring to the Buddhist nun, Cancer Res.2000,60 (9): 2497-503).Moreover, the blood vessel in the mesenchyma stroma of tumors often causes the enhancing of tumor cell to the toleration of cancer therapy drug to conventional chemotherapy medicine and insensitive, consequently treatment failure.
In addition, the cancer drug therapy of low dosage not only can increase the Drug tolerance of cancerous cell, but also can promote the growth of its wettability "; referring to beam etc. " increased after the cancer therapy drug pulse screening human lung carcinoma cell Drug tolerance and external invade the profit ability and with the change of gene expression " " international journal of cancer " 111 phase 484-93 page or leaf (2004) (Liang Y; et al., IntJ Cancer.2004; 111 (4): 484-93).
Therefore, the present invention is directed to the deficiencies in the prior art, a kind of anticancer pharmaceutical composition is provided, more specifically, be entity-tumor-resistant medicine composition, this pharmaceutical composition can suppress or destroy the blood vessel of tumor effectively and can suppress the new vessels of tumor, can suppress tumor cell simultaneously, thereby can better treat tumor, reduce recurrence.
(3) summary of the invention
The present invention is directed to the deficiencies in the prior art, a kind of anticancer pharmaceutical composition is provided, more specifically, is entity-tumor-resistant medicine composition.Decapacitation suppresses can also increase the sensitivity of tumor cell to cancer therapy drug outside the tumor growth.
Anticancer pharmaceutical composition of the present invention comprises anticancer effective component and pharmaceutic adjuvant, anticancer effective component is vasoinhibitor and cancer therapy drug, described cancer therapy drug is to have the medicine that suppresses growth of tumour cell, is selected from one of dichloro ethamine kind drug (bischloroethylamines), paclitaxel kind anti-cancer drugs thing (taxanes), antitumor antibiotics class medicine or antimetabolitas or combination.
The formation that blood vessel suppresses to suppress or to destroy the blood vessel of tumor effectively and can suppress the new vessels of tumor, and then not only make tumor cell lose the required support of growth and the source of nutrient substance, also promoted chemotherapeutics around tumor, to reach infiltration and the diffusion in the tumor tissues.
Above-mentioned vasoinhibitor is selected from one of following or combination:
NSC 609974 (carboxyamidotriazole, CAT), thalidomide (thalidomide, Thalidomide), LS-2616 (linomlde, inhibitors of integrin), En Jisi peptide booth (angiostatin), En Duosi peptide booth (endostatin), VEGF (VEGF) acceptor inhibitor or Tyrosine kinase inhibitor.
Wherein Tyrosine kinase inhibitor is selected from one of following or combination:
Imatinib mesylate (Imatinib mesylate has another name called imatinib mesylate, Glivec),
4-[(4-methyl isophthalic acid-piperazine) methyl]-N-[4-methyl-3-[[4-(3-pyridine)-2-pyrimidine] amino] phenyl]-the aniline mesylate (4-((Methyl-1-piperazinyl) methyl)-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl] amino]-phenyl] benzamide methanesulfonate, STI 571, CGP-57148B, STI-57lA, CGP 57148), 5-[5-fluoro-2-oxygen-1, the 2-indoline-(3Z)-methylene]-2,4-dimethyl-1H-pyrroles-3-carboxylic acid (2 diethyl amino ethyl group) amide (5-[5-Fluoro-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic Acid (2-Diethylaminoethyl) amide, Sutent, SU11248, SU011248)
3,3-two chloro-5-(4-sulfonyloxy methyl yl pyridines)-2-dihydroindole ketone (3,3-Dichloro-5-(4-methylpiperidinosulfonyl)-2-indolinone, DCM),
3-[1-(the 3H-imidazoles-4-yl)-first-(Z)-Ya Neiweng-5-methoxy-l, 3-dihydro-indole-2-dihydroindole ketone (3-[1-(3H-imidazol-4-yl)-meth-(Z)-ylidene]-5-methoxy-1,3-dihydro-indol-2-one, SU9516, SU9518)
1H-pyrroles-3-propanoic acid, 2-[(1,2-dihydro-2-oxygen-3H-indole-3-subunit) methyl]-4-methyl (SU6663, SU-5402,1H-Pyrrole-3-propanoic acid, 2-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene) methyl]-4-methyl)
2H-indole-2-dihydroindole ketone (2H-Indol-2-one),
3-((4,5-dimethyl-1H-pyrroles-2-yl) methylene)-1,3-dihydro-[CAS] (3-((4,5-dimethyl-1H-pyrrol-2-yl) methylene)-1,3-dihydro-[CAS], SU5614, semaxanib, SU-011271, SU-011606, SU-11612)
Pyrroles's lactone dihydroindole ketone (pyrrolyllactone indolinones, SU6577),
The lactams dihydroindole ketone (pyrrolyllactam indolinones, SU6597),
3-(4-dimethylamino-naphthal-1-methylene)-1,3-dihydro-indole-2-dihydroindole ketone (3-(4-Dimethylamino-naphthaleh-1-ylmethylene)-1,3-dihydro-indol-2-one, MAZ51),
1,3-dihydro-5,6-dimethoxy-3-[(4-hydroxyphenyl) methylene]-2H-indole-2-dihydroindole ketone (1,3-dihydro-5,6-dimethoxy-3-[(4-hydroxyphenyl) methylene]-2H-indol-2-indolinone, RPI-1),
3-[5-methyl-2-(2-oxygen-1,2-dihydro-indol-3-yl)-1H-pyrroles-3-methyl]-propanoic acid (3-[5-methyl-2-(2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-1H-pyrrol-3-yl]-proprionic acid, SU10944),
5-[(Z)-(5-chloro-2-oxygen-1,2-dihydro-3H-indole-3-methylene) methyl]-N-(2-(diethylin) ethyl-1H-pyrroles-3-carboxylic acid amides (5-[(Z)-(5-chloro-2-oxo-1,2-dihydro-3H-indol-3-ylidene) methyl]-N-[2-(diethylamino) ethyl]-2,4-dimethyl-1 H-pyrrole-3-carboxamide, SU1l652)
5-[(Z)-(5-fluoro-2-oxygen-1,2-dihydro-3H-indole-3-subunit) methyl]-2,4-dimethyl-N-(2-pyrrolidinyl-1-ethyl)-1H-pyrroles-3-carboxylic acid amides (5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene) methyl]-2,4-dimethyl-N-(2-pyrrolidin-l-ylethyl)-1H-pyrrole-3-carboxamide), SU11654)
5-[(Z)-(5-chloro-2-oxygen-1,2-dihydro-3H-indole-3-subunit) methyl]-2,4-dimethyl-N-(2-pyrrolidinyl-1-ethyl)-1 pyrroles-3-carboxylic acid amides ((5-[(Z)-(5-chloro-2-oxo-1,2-dihydro-3H-indol-3-ylidene) methyl]-2,4-dimethyl-N-(2-pyrrolidin-1-ylethyl)-1H-pyrr01e-3-carboxamide), SU11655)
3-[[3-phenyl-4 (3H)-quinazolinone-2-methyl] TGA] hydrazono-]-the 1H-2-dihydroindole ketone (3-[[(3-phenyl-4 (3H)-quinazolinone-2-yl) mercaptoacetyl] hydrazono]-1H-2-indolinones, SU1 165), 3-two (4-anisyl) methylene-2-dihydroindole ketone (3-bis (4-methoxyphenyl) methylene-2-indolinone, TAS-301)
3-[4-formyl piperazine-4yl]-benzal]-the 2-dihydroindole ketone (3-[4-(1-formylpiperazin-4yl)-bcnzylidenyl]-2-indolinone, SU4984),
3-([5-imidazoles] 2,1-methylene thiazole)-2-dihydroindole ketone (3-(5-imidazo) 2,1-blthiazolylmethylene)-2-indolinone, IBMI),
3-1 (2,6-methylimidazole [2,1-Bj-thiazole-5-yl] methylene-5-methoxyl group-2-dihydroindole ketone (3-1 (2,6-dimethylimidazo[2,1-bJ-thiazol-5-yl] methylenel-5-methoxy-2-indolinone, DMM[, SU9518),
Imidazoles [2,1-b] methylene thiazole-2-dihydroindole ketone (Imidazo[2,1-b] thiazolylmethylene-2-indolinones, ITI),
Methylene indole-2-dihydroindole ketone (indolylmethylene-2-indolinones, IMI),
(2-chloro-indole) methylene-2-dihydroindole ketone (2-chloroindolyl) methylene-2-indolinone, CMI),
Arlydene 2-dihydroindole ketone (arylidene 2-indolinone, AI),
1,3-dihydro-5,6-dimethoxy-3-[(4-hydroxyphenyl) methylene]-2H-indole-2-dihydroindole ketone (1,3-dihydro-5,6-dimethoxy-3-[(4-hydroxyphenyl) methylene]-2H-indol-2-one), Cpd 1),
3-(4-dimethylamino-benzal)-2-dihydroindole ketone (3-(4-dimethylamino-benzylidenyl)-2-indolinone, DMBI),
5-chloro-3-methylene pyridine-2-dihydroindole ketone (5-chloro-3-pyridylmethylene-2-indolinone, CPMI),
3,3-lutidines-1-phenyl-2-dihydroindole ketone (3,3-dipyridylmethyl-1-phenyl-2-indolinone, DPMPI),
E-3-(2-chloro-3-methylene indole) 1,3-indoline-2-dihydroindole ketone (E-3-(2-chloro-3-indolylmethylene) 1,3-dihydroindol-2-indolinone, CIDI),
Gefitinib (Gefitinib, claim 4-quinazoline oxazolone amine again, N-(3-chloro-4 fluoro phenyl)-7-methoxyl group-6-[3-4 morpholine] propoxyl group), 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-4-morpholin] propoxy)
Erlotinib (4-quinazoline oxazolone amine, N-(3-acetenyl)-6, two (2-the methoxy ethyl)-monohydrochloride 4-Quinazolinamine of 7-, N-(3-ethynylphenyl)-6,7-bis (2-methoxyethoxy)-monohydrochlo ride, Tarceva, OSI-774, erlotinib, CP-358774, OSI-774, R-1415)
(phenol, 4-(4-(((1R)-1-phenethyl) amino)-1H-pyrrolo-(2,3-d) pyrimidine-6-yl) (Phenol, 4-(4-(((1R)-1-phenylethyl) amino)-1H-pyrrolo (2,3-d) pyrimidine-6-yl)-, PKI-166, CGP-59326, CGP-59326B, CGP-62706, CGP-74321, CGP-75166, CGP-76627), Lapatinib (4-quinazoline oxazolone amine, N-[3-chloro-4-[(3-fluoro) methoxy ethyl] the 6-[5-[[2-[sulfidomethyl] ethyl] furan-2-yl]] two (4-tolyl sulfate) single hydrate], 4-Quinazolinamine, N-[3-chloro-4-[(3-fluorobenzyl) methoxyphenyl]-6-[5-[[[2-[methylsulfonyl] ethyl] amino] methyl] furan-2-yl]] bis (4-methylbenzenesulfonate) monohydrate, lapatinibditosvlate, GW-2016, GW-572016, GW-572016F)
Votaranib (N-(4-chlorphenyl)-4-(pyridine-4-methyl) faces phenylenedimethylidyne-1-amine (N (4-chlorophenyl)-4 (pyridin-4-ylmethyl) phtalazin-l-amine, vatalanib, PTK-787, PTK/ZK, Schering VEGF-TK1, Schering AG, ZK-222584))
WAY-EKB 569 ((2E)-N-[4-[(3-chloro-4-fluoro phenyl) amine-3-cyanogen-7-ethoxyquin-6-yl]-4-(dimethylamino) also-the 2-amide ((2E)-N-[4-[(3-chloro-4-fluorophenyl) amino]-3-cyano-7-ethoxyquinoljn-6-yl]-4-(dimethy lamino) but-2-enamide, EKB-569, pelitinib).
Other vasoinhibitor is referring to international monopoly (application number: WO 97/22596, WO 97/30035, WO 97/32856 and WO98/13354).
Above vasoinhibitor also comprises their salt, as, but be not limited to sulfate, phosphate, hydrochlorate, Lactobionate, acetate, aspat, nitrate, citrate, purine or pyrimidine salt, succinate and maleate etc.
Preferred one of the following or combination of above-mentioned vasoinhibitor:
NSC 609974 (CAT); Thalidomide; LS-2616; En Jisi peptide booth; En Duosi peptide booth; imatinib mesylate; 5-[5-fluoro-2-oxygen-1; the 2-indoline-(3Z)-methylene]-2; 4-dimethyl-1H-pyrroles-3-carboxylic acid (2-diethylaminoethyl) amide; 3; 3-two chloro-5-(4-sulfonyloxy methyl yl pyridines)-2-dihydroindole ketone (DCM); 3-[1-(the 3H-imidazoles-4-yl)-first-(Z)-Ya Neiweng-5-methoxy-1; 3-dihydro-indole-2-dihydroindole ketone; 1H-pyrroles-3-propanoic acid; 2-[(1; 2-dihydro-2-oxygen-3H-indole-3-subunit) methyl]-the 4-methyl; 2H-indole-2-dihydroindole ketone; 3-((4; 5-dimethyl-1H-pyrroles-2-yl) methylene)-1; 3-dihydro-[CAS]; pyrroles's lactone dihydroindole ketone; the lactams dihydroindole ketone; 3-(dimethylamino-naphthal-1-methylene)-1; 3-dihydro-indole-2-dihydroindole ketone; 1; 3-dihydro-5; 6-dimethoxy-3-[(4-hydroxyphenyl) methylene]-2H-indole-2-dihydroindole ketone; 3-[5-methyl-2-(2-oxygen-1; 2-dihydro-indol-3-yl)-1H-pyrroles-3-methyl]-propanoic acid; 5-[(Z)-(5-chloro-2-oxygen-1; 2-dihydro-3H-indole-3-methylene) methyl]-N-(2-(diethylin) ethyl-1H-pyrroles-3-carboxylic acid amides; 5-[(Z)-(5-fluoro-2-oxygen-1; 2-dihydro-3H-indole-3-subunit) methyl]-2; 4-dimethyl N-(2-pyrrolidinyl-1-ethyl)-1H-pyrroles-3-carboxylic acid amides; 5-[(Z)-(5-chloro-2-oxygen-1; 2-dihydro-3H-indole-3-subunit) methyl]-2; 4-dimethyl-N-(2-pyrrolidinyl-1-ethyl)-1H-pyrroles-3-carboxylic acid amides; 3-[[3-phenyl-4 (3H)-quinazolinone-2-methyl] TGA] hydrazono-)-1H-2-dihydroindole ketone (SU1165); 3-two (4-anisyl) methylene-2-dihydroindole ketone; 3-[4-formyl piperazine-4yl]-benzal]-the 2-dihydroindole ketone; 3-([5-imidazoles] 2; 1-methylene thiazole)-the 2-dihydroindole ketone; 3-1 (2; 6-methylimidazole [2; 1-Bj-thiazole-5-yl] methylene-5-methoxyl group-2-dihydroindole ketone; imidazoles [2; 1-b] methylene thiazole-2-dihydroindole ketone; methylene indole-2-dihydroindole ketone; (2-chloro-indole) methylene-2-dihydroindole ketone; arlydene 2-dihydroindole ketone; 1; 3-dihydro-5; 6-dimethoxy-3-[(4-hydroxyphenyl) methylene]-2H-indole-2-dihydroindole ketone; 3-(4-dimethylamino-benzal)-2-dihydroindole ketone; 5-chloro-3-methylene pyridine-2-dihydroindole ketone; 3; 3-lutidines-1-phenyl-2-dihydroindole ketone; gefitinib; Erlotinib; phenol; 4-(4-(((1R)-1-phenethyl) amino)-1H-pyrrolo-(2; 3-d) pyrimidine-6-base; Lapatinib; ZK-222584; WAY-EKB 569 or E-3-(2-chloro-3-methylene indole) 1,3-indoline-2-dihydroindole ketone.
Above-mentioned vasoinhibitor is with NSC 609974; thalidomide; LS-2616; En Jisi peptide booth; En Duosi peptide booth; the vascular endothelial growth factor receptor inhibitor; imatinib mesylate; 5-[5-fluoro-2-oxygen-1; the 2-indoline-(3Z)-methylene]-2; 4-dimethyl-1H-pyrroles-3-carboxylic acid (2-diethylaminoethyl) amide; 3; 3-two chloro-5-(4-sulfonyloxy methyl yl pyridines)-2-dihydroindole ketone (DCM); 3-[1-(the 3H-imidazoles-4-yl)-first-(Z)-Ya Neiweng-5-methoxy-1; 3-dihydro-indole-2-dihydroindole ketone; 1H-pyrroles-3-propanoic acid; 2-[(1; 2-dihydro-2-oxygen-3H-indole-3-subunit) methyl]-the 4-methyl; the 2H-indol-2-one; 3-((4; 5-dimethyl-1H-pyrroles-2-yl) methylene)-1; 3-dihydro-[CAS]; gefitinib; Erlotinib; phenol; 4-(4-(((1R)-1-phenethyl) amino)-1H-pyrrolo-(2,3-d) pyrimidine-6-base; Lapatinib; ZK-222584 or WAY-EKB 569 are preferred.With NSC 609974, thalidomide, LS-2616, imatinib mesylate, gefitinib, Erlotinib, Lapatinib, ZK-222584 or WAY-EKB 569 for most preferably.
Above-mentioned dichloro ethamine kind drug is selected from one of following or combination:
Chlorambucil (chlorambucil, chlorambucil), cyclophosphamide (Cyclophosphamide, CTX), 4H-peroxide cyclophosphamide (4H-CTX), ifosfamide (Ifosfamide, Isophosphamide), three mustard cyclophosphamide, sufosfamide (Sufosfamide), defosfamide (Defosfamide), Mafosfamide (Mafosfamide), perfosfamide (Perfosfamide), trofosfamide (Trofosfamide), thiocarzolamide, melphalan (Melphalan), metamelfalan (Metamelfalan), methoxymerphalan (Methoxymerphalan), formylmerphalan (Formylmerphalan), hexamethylmelamine (hexamethylmelamine), Ametantrone, Thymopentin, clomifene, letrozole, disodium cantharidinate, cantharidin (cantharidine), sodium cantharidinate, N-methylcantharidimide, N-hydroxycantharidin, norcantharidin (Norcantharidin), thiocolciran, sarcolysine, methasquin, NSC-1895, mannomustine (Mannosulfan), treosulfan (Treosulfan), ritrosulfan (Ritrosulfan), an improsulfan (Improsulfan), Z 7557, Spirobromin, d-mannitobusulphan, cis-diamminetetrachloroplatinum, enpromate, epipropidine, ethoxene, bimolane, second hydroxyl urea, ethyliminum, etoglucid (etoglucid, Ethoglucid, Etoglucid), benefit hair phosphorus ammonium, E39, pipobroman (pipobroman, Pipobroman), piposulfan (A-20968, Piposulfan), Li Chuikexin, Dup 942, NSC 122402, radioplex, rofecoxib, taxodione, trimethylolmelamine, urethane, Zorubicin Hydrochloride, RP-22050, triethylenemelaine (triethylenemelamine), epoxypiperazine (epoxypiperazine), benzene assistant TEPA (Benzodepa), Phopurine (Pumitepa), meturedepa (Meturedepa), Ah bundle's TEPA (Aza-TEPA), the salt of urethimine (Uredepa) or said medicine.
Above-mentioned dichloro ethamine kind drug serves as preferred with Chlorambucil, cyclophosphamide, ifosfamide, melphalan, 4H-peroxide cyclophosphamide, methoxymerphalan, hexamethylmelamine, letrozole, cantharidin, norcantharidin or Ah bundle's TEPA.
The salt of above-mentioned dichloro ethamine kind drug comprises: sulfate, phosphate, hydrochlorate, Lactobionate, acetate, aspat, nitrate, citrate, purine or pyrimidine salt, succinate or maleate.
The percentage by weight of dichloro ethamine kind drug in compositions is good from 0.01%-99.99% with 1%-50%, is best with 5%-30%.
The paclitaxel kind anti-cancer drugs thing is selected from one of following or combination:
Paclitaxel (Paclitaxel, taxol, taxol), Docetaxel (Docetaxel, taxotere, docetaxel) and the derivant of paclitaxel, as, but be not limited to, 2 '-hydroxyl taxol (paclitaxel-2 '-hydroxy), 10-go the acetyl Baccatine III (10-deacetylbaccatin III, DAB), 14 beta-hydroxies-10-removes acetyl Baccatine III (14-OH-DAB), 9-dihydro-13-Baccatine III (DHB), IDN5109,10-removes acetyl taxol (10-deacetyl taxol), 7-table-taxol (7-epi-taxol), Tetraol, Baccatine III (baccatin III), Tetraol V, Semen Caesalpiniae Ramulus et folium taxi cuspidatae (Taxus brevifolia), ground hemlock (Taxus Canadensis), yew (Taxus baccata) and Chinese Ramulus et folium taxi cuspidatae (Taxus chinensis), pointed tooth Ramulus et folium taxi cuspidatae (Taxuscuspidata), cultivate Ramulus et folium taxi cuspidatae (Taxus X media cultivars), Yunnan Ramulus et folium taxi cuspidatae Taxus yunnanensis), Florida Ramulus et folium taxi cuspidatae (Taxusfloridana) or their salt.
It serves as preferred that above-mentioned paclitaxel kind anti-cancer drugs thing goes acetyl Baccatine III, 14 beta-hydroxies-10-to go acetyl Baccatine III, 9-dihydro-13-Baccatine III, 10-to remove acetyl taxol and 7-table-taxol with paclitaxel, Docetaxel (docetaxel), 2 '-hydroxyl taxol, 10-.
The percentage by weight of above paclitaxel kind anti-cancer drugs thing in compositions is 1-50%.
Antitumor antibiotics class medicine is selected from one of following or combination:
Carcinomycin, bleomycin (Bleomycin, Bleomycin A5, Pingyangmycin), (hydrochloric acid) bleomycin, zorbamycin, the piperazine bleomycin, sulphuric acid piperazine bleomycin, antibiotic 1588, bouvardin, clarithromycin (Clarithromycin), aklavine (Aclacinomycin A, aclarubicin), aklavine-B, 9-[4-(N-Methylacetamido)anilino, 9-(4-(N-Methylacetamido)anilino)-7-methyl-1H-imidazo(4,5-f)quinoline, kidamycin, acetylkitamycin (acetyl kidamycin), azotomycin (azotomycin), daunomycin (rubidomycin, daunorubicin, daunomycin), Diacetoxysciroenol (Diacetoxysciroenol), doxorubicin hydrochloride (doxorubicin, doxorubicin, adriamycin), triferricdoxorubicin, epirubicin (epiadriamycin) or epirubicin (Epirubicin), Valrubicin (valrubicin), pirarubicin, 7-O-methyl Nuo Jia-4 '-epirubicin (7-o-methylnogallol-4 '-epiadriamycin), diethoxy acetyl amycin, ciclamicin, mitomycin (Mitomycin), ametycin (mitomycin C), NSC-69529, actinomycin D (Dactinomycin), actinomycin C, cyclosporin A, Carzinocidin (carzinocidin), carzinophillin (carzinophylin), cardinophyllin, the tumor rhzomorph, carzinostatin (carzinostatin, carcinostain), neocarzinostain NCS (neocarzinostain), diazamycine (diazamycine), Macrocin (macrocin), macrocinomycin (macrocinomycin), dactinomycin, alanopsin, alazopeptin, the A Le lid, neothricin (neothricin, neothramycin), macromycin (macromomycin or macromycin), neothramycin A, nocardin (nocardin), nocardorubin. (nocardorubin), 2-[N-(2-amidinoethyl)carbamoyl (noformicin), nogalamycin (promise Garamycin, nogalamycin or nogaromycin), Mitochromine mitocromine B-35251 (mitochromine or mitocromine), polymyxin E (PolymyxinE), pirlimycin (Pirlimycin), dirithromycin (Dirithromycin), antramycin, oxalysine, duazomycin, Olivomycin, rufocromomycin, NSC-45384, streptozotocin, peplomycin, puromycin, sparsomycin, talisomycin, Anthrapyrazole, losoxantrone (Losoxantrone), mitoxantrone (Mitoxantrone), piroxantrone (Piroxantrone), teloxantrone (Teloxantrone), hydroxyl nitre D-glucosamine ring element, anthramycin (anthramycin, antramycin), methylanthramycin, Ai Fei ground can be peaceful, asperlin, (hydrochloric acid) Carrninomycin I, talisomycin, macromycin, O-Demethyldaunomycin, NSC-178248, chromomycin A3, chlorine assistant star (chlorozotocin), demethylrifampicin, ditrisarubicins, Hitachimycin, deoxycoformycin, puromycin, puromycin hydrochloride, rachelmycin, rebeccamycin, Sangivamycin, sarkomycin, sibiromycin, talisomycin, rice holder Zuro, selenazofurin, Antibiotic BMG-162aF2, spirogermanium hydrochloride, Spirogermanium, Spirophydantoin Mustard, stibcytostatum.
Above-mentioned antitumor antibiotics medicine serves as preferred with bleomycin, daunomycin, aclarubicin, amycin, epirubicin, pirarubicin, Valrubicin, ametycin, actinomycin D, losoxantrone, mitoxantrone, piroxantrone, teloxantrone or chlorine assistant star.
Above antitumor antibiotics medicine also comprises its salt, as, but be not limited to sulfate, phosphate, hydrochlorate, Lactobionate, acetate, aspat, nitrate, citrate, purine or pyrimidine salt, succinate or maleate.
Antimetabolitas is selected from one of following or combination: comprise, pemetrexed (Alimta), pemetrexed disodium, Rumi Qu Sai, doxifluridine (Doxifloridine, fortulon), the 5-doxifluridine, floxuridine (fluridine), propylthiouracil, fluorouracil (Fluoracil, Fluracil), the fluorobutane uracil, 5-fluorouracil (Fluorouracil, 5-FU), tegadifurum, the 5-fluoxydin, sulfomercaprine sodium, mercaptopurine (Mercaptopurine, happy disease is peaceful, 6-MP), mercapto miaow purine, Ismipur, the adenine hydrochlorate, Benin, thioguanine (thioguanine, 6-TG), sulfur crow purine, tisupurin, Hydrazinium sulfate, dianhydrogalactitol, Aziridinyl Benzoquinone, but sweet smell Luoning, isoeuxanthone, chalone, chlorine is bent phosphoric acid, clastoban, cycloleucine, look into the Chinese holly woods, methyl yellow is looked into the Chinese holly woods sourly, Bai Ruikuaer, oxipurinol, Australia Ma Lite, bromine crust acid (sodium), Brytoslatin-I, bromine urea glycosides, fluorine urea hexylamine, folic acid, methotrexate (methotrexate, MTX), 10-ethyl denitrification aminopterin (deaza-aminopterin), fluoromethotrexate, the dioxy methotrexate, 5, the 10-lonetrexol, N5-Methyltetrahydrohmofotic Acid, buthiopurin, his amide of Dinke, Guang azepine crow glycosides, carmofur (Carmofur), ftorafur (Tegafur, tegafur, FT-207), Tegafur-uracil mixt., 6-prenylindole, 6-thioinosine, UFT (Tegafur-Uracil, UFT), coralyne, N-foymylsarcolysin, ammonia (base) pterin (aminopterin), aminopterin sodium (Aminopterin Sodium), 8-azaguanine (8-azaguanine), 6-dimethylamino-8-azaadenosine, (nitro) imuran (azathioprine), uracil, 5-mercaptomethyluracil, azaserine (azaserine), Raltitrexed (Raltitrexed), nolatrexed dihydrochloride, sophoridine, formyl tetrahydrofolic acid, 5-methyltetrahydrohomofolate, Zoledronate, thunder accounts for for song, the temozolomide, bicalutamide, asparaginase (L-Asparaginase, left-handed asparagine), calcium levofolinate, calcium folinate (Calcium Levofolinate, calcium leucovorin), Quinespar, triazinate, trimetrexate, tramadol, the 5-chlorobarbituric acid, 5-diazonium uracil, piracetam, hycamtin, topotecan hydrochloride, ZD-9331, BHAC, SM108, cytosine arabinoside (cytosine arabinoside, Cytarabine (Ara-C)), ancitabine (cyclotidine, Cyclocytidine), hydroxyurea (Hydroxycarbamide, hydroxyurea), the hydroxyl guanidine, the 5-fluorouracil nucleoside, the 5-fluorouracil deoxynucleoside claims fluorouracil deoxynucleoside (floxuridine) again, glycerol Citrus chachiensis Hort. alkali, A Lei can loose, HCFU, 5 ' DFUR, TK-177, isoxazole acetic acid, aminoglutethimide (ethylbenzene amine piperidones, aminoglutethimidium, aminoglutethimide), amonafide, 5-chloro-5-deoxyarabinosylcytosine, atamestane, azacytidine (Azacitidine, 5-azacytidine, the atropic cytidine, AzGR), chloramphenalan (betamerphalan, Betamerphalan), decitabing, dexrazoxane (Dexrazoxane), crisnatol, cristatic acid, carat is sharp flat, the sharp guest of carat, galocitabine (Galocitabine), gemcitabine (Gemcitabine), ibacitabine (Ibacitabine), enocitabine (Enocitabine), ancitabine (Ancitabine), decitabine (Decitabine), flurocitabine (Flurocitabine), capecitabine (Capecitabine), enocitabine, his shore of imidazoles, the non-Shandong of Crane, the OK a karaoke club amide, carzolamide, carbazylquinone, CB-1-252, curcumin, the curcumin diketone, ketotrexate, trimetrexate, Si Poguning, deoxidation Si Poguning, naphthalene urea phosphamide, Ditercalinium Chloride, F-ara AMP-2, fluorine benzyl thiophene ketone, gamlogic acid, goserelin, nitrogen Chinese holly mountain range, Hellebrigenin, inosine dialdehyde, metoprine, mitobronitol (Dibromomannitol, Mitobronitol), mitolactol (Mitolactol), Ke is for ground, Persian, eriolangin, dopan (Chlorethylaminouracil, Dopan), Mei Luogerui, Methyl GAG, GR 30921X, mitotane, fazarabine (Fazarabine), fludarabine (fludarabine), cladribine (cladribine), pentoside (pentostatin), phenaline, benzene comes U.S. special, phosphemide, hair Buddhist nun azoles, Polyprenic Acid, Pteroylaspartic Acid, pteroyltriglutamic acid, fast rice tongue pool, riboprine, simtrazene, Schizophyllan, sodium bromebrate, Solvent Yellow 3, bent fourth sulphur ester, TEM, triaziquone, triciribine, TCN-P NSC-280594, triptolide, triptorelin, nine cloth Lip river azoles, UFT, vitamin B-17, Wei Maining, z-azepine adenosine, prick western cytidine, epipropidine (Epipropidine), the A Monuo phase, adozelesin (Adozelesin), acronine (Acronine), alanosine (Alanosine), ametantrone (Ametantrone), Anastrozole, the A Naxi army, anaxirone (Anaxirone), A Si Yin wakes up, acivicin (Acivicin), atevirdine (Atevirdine), idoxifene (idoxifene), AT-236, hold high and rather study carefully Ji, individual Lu Dabuxin, antineoplaston, antineoplastons, asaphan, Aspargus Granule, AT-346, Bai Ruikuaer (sodium), (hydrochloric acid) Orang Crush, granisetron, tropisetron, dacarbazine, ondansetron, thymosin, tramadol, imatinib mesylate, diclofenac, Thalidomide, the holder fluorine kills star, toremifene, ambroxol, lappaconitine, anti-general etc. because of, thymosin, flutamide, ethyliminum, amine benzene, neoquini oxydum, the N-methylformamide, the jail can reach azoles, NSC-56045, oxisuran, oxylycorine, paphencyl, it is fixed to moor damp Nip, the penberol, prospidine chloride, protoanemonin, good generation born of the same parents, retelliptine, Sensorad, M3, solapalmitine, solaziquonum, stibenemidine, Temozoromide, the many Shillongs of platform, thiaolivacine, bifurcation pyridine of nitre ammonia or SN-11841.
Above-mentioned antimetabolitas is with Ismipur, 5-fluorouracil (5-FU), pemetrexed, pemetrexed disodium, Rumi Qu Sai, doxifluridine, floxuridine, mercaptopurine, thioguanine, methotrexate, carmofur, ftorafur, galocitabine, ibacitabine, enocitabine, ancitabine, decitabine, flurocitabine, enocitabine, his shore of imidazoles, GR 30921X, mitotane, cytosine arabinoside, hydroxyurea, the 5-fluorouracil nucleoside, capecitabine, gemcitabine, fludarabine, thunder accounts for for song, Raltitrexed, the atropic cytidine, dexrazoxane, cladribine or pentoside are preferred.Antimetabolitas can stop the synthetic of DNA in different links respectively, suppresses the cell division increment, and cell cycle and DNA are synthetic to play a role by influencing.
In the anticancer pharmaceutical composition of the present invention anticancer effective component be a kind of or several vasoinhibitors and or a kind of combination of or several anticarcinogens, the anticancer effective component preferred compositions is as follows:
(1) NSC 609974, thalidomide, LS-2616, En Jisi peptide booth, En Duosi peptide booth, the vascular endothelial growth factor receptor inhibitor, imatinib mesylate, 5-[5-fluoro-2-oxygen-1, the 2-indoline-(3Z)-methylene]-2,4-dimethyl-1H-pyrroles-3-carboxylic acid (2-diethylaminoethyl) amide, 3,3-two chloro-5-(4-sulfonyloxy methyl yl pyridines)-2-dihydroindole ketone (DCM), 3-[1-(the 3H-imidazoles-4-yl)-first-(Z)-Ya Neiweng-5-methoxy-1,3-dihydro-indole-2-dihydroindole ketone, 1H-pyrroles-3-propanoic acid, 2-[(1,2-dihydro-2-oxygen-3H-indole-3-subunit) methyl]-the 4-methyl, the 2H-indol-2-one, 3-((4,5-dimethyl-1H-pyrroles-2-yl) methylene)-1,3-dihydro-[CAS], gefitinib, Erlotinib, phenol, 4-(4-(((1R)-1-phenethyl) amino)-1H-pyrrolo-(2,3-d) pyrimidine-6-base, Lapatinib, ZK-222584 or WAY-EKB 569 and Chlorambucil, cyclophosphamide, ifosfamide, melphalan, 4H-peroxide cyclophosphamide, methoxymerphalan, hexamethylmelamine, letrozole, cantharidin, the combination of norcantharidin or Ah bundle's TEPA;
(2) NSC 609974, thalidomide, LS-2616, En Jisi peptide booth, En Duosi peptide booth, the vascular endothelial growth factor receptor inhibitor, imatinib mesylate, 5-[5-fluoro-2-oxygen-1, the 2-indoline-(3Z)-methylene]-2,4-dimethyl-1H-pyrroles-3-carboxylic acid (2-diethylaminoethyl) amide, 3,3-two chloro-5-(4-sulfonyloxy methyl yl pyridines)-2-dihydroindole ketone (DCM), 3-[1-(the 3H-imidazoles-4-yl)-first-(Z)-Ya Neiweng-5-methoxy-1,3-dihydro-indole-2-dihydroindole ketone, 1H-pyrroles-3-propanoic acid, 2-[(1,2-dihydro-2-oxygen-3H-indole-3-subunit) methyl]-the 4-methyl, the 2H-indol-2-one, 3-((4,5-dimethyl-1H-pyrroles-2-yl) methylene)-1,3-dihydro-[CAS], gefitinib, Erlotinib, phenol, 4-(4-(((1R)-1-phenethyl) amino)-1H-pyrrolo-(2,3-d) pyrimidine-6-base, Lapatinib, ZK-222584 or WAY-EKB 569 and paclitaxel, docetaxel, 2 '-hydroxyl taxol, 10-removes the acetyl Baccatine III, 14 beta-hydroxies-10-removes the acetyl Baccatine III, 9-dihydro-13-Baccatine III, 10-goes the combination of acetyl taxol or 7-table-taxol;
(3) NSC 609974, thalidomide, LS-2616, En Jisi peptide booth, En Duosi peptide booth, the vascular endothelial growth factor receptor inhibitor, imatinib mesylate, 5-[5-fluoro-2-oxygen-1, the 2-indoline-(3Z)-methylene]-2,4-dimethyl-1H-pyrroles-3-carboxylic acid (2-diethylaminoethyl) amide, 3,3-two chloro-5-(4-sulfonyloxy methyl yl pyridines)-2-dihydroindole ketone (DCM), 3-[1-(the 3H-imidazoles-4-yl)-first-(Z)-Ya Neiweng-5-methoxy-1,3-dihydro-indole-2-dihydroindole ketone, 1H-pyrroles-3-propanoic acid, 2-[(1,2-dihydro-2-oxygen-3H-indole-3-subunit) methyl]-the 4-methyl, the 2H-indol-2-one, 3-((4,5-dimethyl-1H-pyrroles-2-yl) methylene)-1,3-dihydro-[CAS], gefitinib, Erlotinib, phenol, 4-(4-(((1R)-1-phenethyl) amino)-1H-pyrrolo-(2,3-d) pyrimidine-6-base, Lapatinib, ZK-222584 or WAY-EKB 569 and bleomycin, daunomycin, aclarubicin, amycin, epirubicin, pirarubicin, Valrubicin, ametycin, actinomycin D, losoxantrone, mitoxantrone, piroxantrone, the combination of teloxantrone or chlorine assistant star; Or
(4) NSC 609974; thalidomide; LS-2616; En Jisi peptide booth; En Duosi peptide booth; the vascular endothelial growth factor receptor inhibitor; imatinib mesylate; 5-[5-fluoro-2-oxygen-1; the 2-indoline-(3Z)-methylene]-2; 4-dimethyl-1H-pyrroles-3-carboxylic acid (2-diethylaminoethyl) amide; 3; 3-two chloro-5-(4-sulfonyloxy methyl yl pyridines)-2-dihydroindole ketone (DCM); 3-[1-(the 3H-imidazoles-4-yl)-first-(Z)-Ya Neiweng-5-methoxy-1; 3-dihydro-indole-2-dihydroindole ketone; 1H-pyrroles-3-propanoic acid; 2-[(1; 2-dihydro-2-oxygen-3H-indole-3-subunit) methyl]-the 4-methyl; the 2H-indol-2-one; 3-((4; 5-dimethyl-1H-pyrroles-2-yl) methylene)-1; 3-dihydro-[CAS]; gefitinib; Erlotinib; phenol; 4-(4-(((1R)-1-phenethyl) amino)-1H-pyrrolo-(2,3-d) pyrimidine-6-base; Lapatinib; ZK-222584 or WAY-EKB 569 and Ismipur; 5-fluorouracil (5-FU); pemetrexed; pemetrexed disodium; Rumi Qu Sai; doxifluridine; floxuridine; mercaptopurine; thioguanine; methotrexate; carmofur; ftorafur; galocitabine; ibacitabine; enocitabine; ancitabine; decitabine; flurocitabine; enocitabine; his shore of imidazoles; GR 30921X; mitotane; cytosine arabinoside; hydroxyurea; the 5-fluorouracil nucleoside; capecitabine; gemcitabine; fludarabine; thunder accounts for for song; Raltitrexed; the atropic cytidine; dexrazoxane; the combination of cladribine or pentoside.
Vasoinhibitor percentage by weight concrete condition and deciding in compositions can be good with 1%-70% from 0.01%-99%, is best with 2%-40%.When vasoinhibitor and cancer therapy drug use in conjunction, the weight ratio of the two can be 1: 9 to 9: 1.Cancer therapy drug is percentage by weight 1-50% in compositions.
Pharmaceutic adjuvant of the present invention can be through enzyme, soda acid or tissue fluid hydrolysis or degraded, comprises one of following or its combination:
(1) biocompatibility polymer, comprise biodegradable or biological nondegradable polymer and composition thereof or copolymer, (2) water-soluble low-molecular chemical compound is or/and (3) are used to realize the suitable additive and the excipient of pharmaceutical dosage forms such as injection and slow releasing agent.
Above-mentioned biodegradable polymer comprises natural and/or synthetic polymer.Synthetic polymer as, but be not limited to, polyanhydrides, polyhydroxy acid, polyester (polyesters), polyamide (polyamides), polypeptide (polypeptides), polyactide (polylactides) is as polylactic acid (polylactic acid), polyactide and glycolide copolymer (as the copolymer (PLGA) of glycolic and lactic acid), poe (polyorthoesters), polyphosphazene (polyphosphazenes), to carboxy phenyl propane (p-CPP), certain herbaceous plants with big flowers diacid (sebacic acid, SA), polifeprosan (to the copolymer of carboxy phenyl propane (p-CPP)) with certain herbaceous plants with big flowers diacid (SA), liposome, Polyethylene Glycol (polyglycolide) (polymer of hydroxyacetic acid and lactic acid), carboxylic acids (carboxylic acids), fatty acid (fatty acids), phospholipid (phospholipids), nucleic acid (nucleic acids), polyamino acid (polyamlnoacids), aminoacid such as phenylalanine (phenylalanine), tyrosine (tyrosine), different bright (isoleucine), polynucleotide (polynucleotides); Natural polymer as, but be not limited to, protein and polysaccharide (polysaccharides) comprise hyaluronic acid (hyaluronic acid), chondroitin sulfate (chondroitin sulfate), collagen protein, gelatin, albumin etc.Wherein, preferred polymer is polifeprosan, polyactide, Polyethylene Glycol or polyactide and glycolide copolymer (as the copolymer (PLGA) of glycolic and lactic acid).
Above-mentioned polyanhydrides can be selected for use, but is not limited to, fragrant polyanhydride, aliphatic polyanhydride; Wherein fragrant polyanhydride will be separated slower, the fusing point height, and dissolubility is low in the organic solvent, however the copolymer of fragrant polyanhydride and aliphatic polyanhydride is comparatively desirable (United States Patent (USP) 4757128) but.Representative wherein is polifeprosan (to the copolymer of carboxy phenyl propane (p-CPP) and certain herbaceous plants with big flowers diacid (SA)), and is fragrant polyanhydride to carboxy phenyl propane, and the certain herbaceous plants with big flowers diacid then is the copolymer of an aromatic diacid and a fat diacid.The copolymer of available other fragrance or aliphatic polyanhydride has a detailed description (US4857311 in other United States Patent (USP); 4888176; 4789724).
Above-mentioned polyhydroxy acid can be selected for use, but is not limited to, the copolymer (PLGA) of mixture, glycolic and the lactic acid of polylactic acid (PLA), polyglycolic acid (PGA), polylactic acid (PLA) and polyglycolic acid.Above polyhydroxy acid can singly select or multiselect, and when singly selecting, the molecular weight of polylactic acid (PLA) can be, but is not limited to, 5000-100, and 000, but with 10,000-50,000 is preferred, with 10,000-30,000 for most preferably; The molecular weight of polyglycolic acid can be, but is not limited to, 5000-100, and 000, but with 10,000-50,000 is preferred, with 10,000-20,000 for most preferably; The molecular weight of the copolymer of glycolic and lactic acid (PLGA) can be, but is not limited to, 1000-100, and 000, but with 10,000-50,000 is preferred; With 10,000-20,000 for most preferably; When multiselect, compound polymer or the copolymer formed with macromolecule polymer or different macromolecule polymer serve as preferred, with the compound polymer that contains different molecular weight polylactic acid or certain herbaceous plants with big flowers diacid or copolymer for most preferably, as, but be not limited to, molecular weight is 5000 to 10000 polylactic acid with molecular weight is that 20000 to 50000 polylactic acid mixes, molecular weight is 10000 to 20000 polylactic acid with molecular weight is that 30000 to 80000 PLGA mixes, molecular weight is that 5000 to 10000 polylactic acid mixes with the certain herbaceous plants with big flowers diacid, molecular weight is that 30000 to 80000 PLGA mixes with the certain herbaceous plants with big flowers diacid.When PLA and PGA mixing, its content percentage by weight is respectively 0.1-99.9% and 99.9-0.1%.Compositions can discharge effective ingredient by the mode of direct diffusion and/or degraded.Above molecular weight peak value scope is mainly GPC and records.
The nondegradable polymer of above-mentioned biology comprises, but be not limited to: polyethylene propylene (polyvinyl propylene), polyvinylpyrrolidone (polyvinylpyrrolidone, PVP), organosilicon polymer, ethylene vinyl acetate copolymer (Ethelene-vinyl acetate copolymer, EVAc), polyacrylonitrile (polyacrylonitriles), polyurethanes (polyurethanes), silicone (silicone) and polyphosphazene (polyphosphazenes) etc.Compositions can discharge effective ingredient by the mode of direct diffusion.
For regulating other characteristic of drug releasing rate or change entity-tumor-resistant medicine composition of the present invention, can change the composition and the proportioning of monomer component or molecular weight, interpolation or the adjusting pharmaceutic adjuvant of polymer, add the water-soluble low-molecular chemical compound, as, but be not limited to various sugar or salt etc.Wherein sugar can be, but is not limited to, xylitol, oligosaccharide and chitin etc., and wherein salt can be but is not limited to, potassium salt or sodium salt etc.
The used pharmaceutic adjuvant of entity-tumor-resistant medicine composition of the present invention can be any or multiple material in the above-mentioned pharmaceutic adjuvant, but with the high molecular weight water soluble polymer is main separation, in various high molecular polymers, with polylactic acid, certain herbaceous plants with big flowers diacid, the mixture or the copolymer that contain the macromolecule polymer of polylactic acid or certain herbaceous plants with big flowers diacid is first-selection, mixture and copolymer can be selected from, but be not limited to the mixture or the copolymer of the mixture of PLA, PLGA, PLA and PLGA, certain herbaceous plants with big flowers diacid and fragrant polyanhydride or aliphatic polyanhydride.Polylactic acid (PLA) and polyglycolic acid the blend ratio be 10/90-90/10 (weight), 25/75-75/25 (weight) preferably.The method of blend is arbitrarily.Content when glycolic and lactic acid copolymerization is respectively percentage by weight 10-90% and 90-10%.The representative of fragrance polyanhydride is to carboxy phenyl propane (p-CPP), content during to carboxy phenyl propane (p CPP) and the copolymerization of certain herbaceous plants with big flowers diacid is respectively percentage by weight 10-60% and 20-90%, the blend weight ratio is 10-40: 50-90, preferably weight ratio 15-30: 65-85.
Pharmaceutic adjuvant has a detailed description in " pharmaceutic adjuvant complete works " (the 123rd page, Sichuan science tech publishing house published in 1993, Luo Mingsheng and Gao Tianhui chief editor).In addition, Chinese patent (application number 96115937.5; 91109723.6; 9710703.3; 01803562.0) and U.S.'s patent of invention (patent No. 5,651,986) also enumerated some pharmaceutic adjuvant.Comprise filler, solubilizing agent, absorption enhancer, film former, gellant, system (or causing) hole agent, excipient or inhibitor.Above pharmaceutic adjuvant has has multiple action, and therefore the material of the same race that has is listed in different classifications.The available holder of composition for treating solid tumor of the present invention can be any or multiple material in the above-mentioned pharmaceutic adjuvant, and not exclusively comes the technical characterictic of limit combination according to its classification or definition.
The effective ingredient of entity-tumor-resistant medicine composition can be packaged in the whole pharmaceutic adjuvant equably, also can be packaged in carrier holder center or its surface; Can effective ingredient be discharged by direct diffusion or through mode or dual mode like this that polymer is degraded.In addition, the effective ingredient of composition for treating solid tumor also can be packaged in the liposome equably, or makes microsphere with art methods.
Characteristics of the present invention are that used pharmaceutic adjuvant removes the high molecular polymerization beyond the region of objective existence, also contain above-mentioned any one or multiple other pharmaceutic adjuvant.The pharmaceutic adjuvant that adds is referred to as additive.Additive can be divided into filler, porogen, excipient, dispersant, isotonic agent, preservative agent, inhibitor, solubilizing agent, absorption enhancer, film former, gellant etc. according to its function.
Pharmaceutic adjuvant also can be liquid, as, but be not limited to Oleum sesami, suspension, distilled water, physiology towards liquid and semisolid, as (but being not limited to) fruit jelly, paste, ointment etc., above-mentioned pharmaceutic adjuvant is applicable to the compositions that contains or do not contain additive.
The action effect of methods such as conventional chemotherapy, immunization therapy, high thermal therapeutical, photochemical therapy, electrotherapy, Biotherapeutics, hormone therapy, magnetic therapy, ultrasonic therapeutic, radiotherapy and gene therapy is strengthened.Therefore when local slow discharges, can share, thereby its anticancer effect is further strengthened with above-mentioned non-operative treatment.
When share with above-mentioned non-operative treatment, entity-tumor-resistant medicine composition of the present invention can be used simultaneously with non-operative treatment, also can use in non-operative treatment is implemented a few days ago, and its purpose is to strengthen as far as possible the sensitivity of tumor.Vasoinhibitor has potentiation significantly to act on to the nitrosourea cancer therapy drug, thereby provide a kind of more effective new method for effecting a radical cure former of various human bodies and animal and shifting entity tumor, have very high clinical value and remarkable economical and social benefit.
Route of administration
Entity-tumor-resistant medicine composition of the present invention can be used through various approach, as in passages through which vital energy circulates, tremulous pulse, subcutaneous, muscle, Intradermal, intracavity, the tumor, tumor week etc.Route of administration depends on multiple factor, for obtaining valid density in position, tumor place, medicine can give through other number of ways, as arterial perfusion optionally, administration in the intra-bladder instillation (intracavitary), abdominal cavity (intraperitoneal) or thoracic cavity (intrapleural) and canalis spinalis.In number of ways, with topical, as with in selective arterial, the tumor, tumor week injection or be placed as the master, with in the tumor, the form that slowly discharges of tumor week or tumor chamber serve as preferably, can plant slow-releasing pump and slow releasing capsule or sustained release profile in vivo test implant as selecting for use.
When the effective ingredient of entity-tumor-resistant medicine composition is vasoinhibitor, this entity-tumor-resistant medicine composition is based on topical, as with in selective arterial, the tumor, tumor week injection or be placed as the master, with in the tumor, the form that slowly discharges of tumor week or tumor chamber serve as preferably, as slow releasing agent, implant or sustained-release implant.
Dosage
The consumption of cancer therapy drug depends on several factors, as, but be not limited to gross tumor volume, patient body weight, administering mode, disease progression situation and therapeutic response.But its principle is to reduce the repair ability of tumor cell to DNA, increases the action effect of therapies such as chemotherapy.The effective dose of vasoinhibitor is 1-800 milligram/kg body weight, is ideal with 10-500 milligram/kg body weight, with 20-200 milligram/kg body weight for the most desirable.Vasoinhibitor shared ratio in compositions is decided because of concrete condition, is good with 1%-70%, is best with 2%-40%.
When used the part, its blood level maintained reduced levels, and concentration maintains higher level in the tumor.
When vasoinhibitor and cancer therapy drug use in conjunction, the ratio of the two can be 1: 9 to 9: 1, and the effective dose of cancer therapy drug is 0.01-200 milligram/kg body weight, is ideal with 1-30 milligram/kg body weight, with 2-20 milligram/kg body weight for the most desirable.
Entity-tumor-resistant medicine composition of the present invention can be used for the treatment of the people and animal can be planted tumor, comprise entity tumor, blood and lymph tumor etc., but mainly treat the medicine of people's various entity tumors, comprise and originate from brain with preparation, the central nervous system, kidney, liver, gallbladder, incidence, the oral cavity, thyroid, skin, mucosa, body of gland, blood vessel, osseous tissue, lymph node, lungs, esophagus, stomach, mammary gland, pancreas, eyes, nasopharynx part, the uterus, ovary, endometrium, cervix uteri, prostate, bladder, colon, former or cancer or sarcoma or the carcinosarcoma that shifts of rectum.
Entity-tumor-resistant medicine composition of the present invention also can be used to prepare the medicine of the above-mentioned various entity tumors for the treatment of house pet and animal, when being used for the treatment of the various entity tumor of house pet and animal.
Also can add other medicinal ingredient in the entity-tumor-resistant medicine composition of the present invention, as, but be not limited to antibiotics, antalgica, anticoagulant medicine, hemorrhage etc.Above medicinal ingredient can singly select or multiselect, can join the compositions that contains or do not contain additive, and its content is because of specifically deciding.
Above-mentioned effective ingredient is packaged in the pharmaceutic adjuvant, then topical application.Said composition can with topical, wherein be released to the best with local slow again as injection in selective arterial injection and the direct tumor body for good through various administrations.When used the part, composition for treating solid tumor of the present invention can directly place around former or the entity tumor that shifts or in the tumor body, also can directly place former or all or part of excision of entity tumor shifted formed intracavity afterwards.
Entity-tumor-resistant medicine composition Main Ingredients and Appearance of the present invention is a holder with the bio-capacitivity material, so do not cause foreign body reaction.Support to place in the object back degradable and absorb, so no longer operation is taken out.Cause discharges contained drug at tumor by local, thereby optionally improves and prolong local drug concentration, can reduce the general toxic reaction that is caused by the conventional route administration simultaneously.
Entity-tumor-resistant medicine composition of the present invention can be made into multiple dosage form.As, but be not limited to injection, muddy suspension, ointment, capsule, slow releasing agent, implant, implantation slow release agent etc.; Be different shape, as, but be not limited to granular, lamellar, sphere, bulk, needle-like, bar-shaped and membranaceous.In various dosage forms, based on agent for slow releasing in the body.Above-mentioned dosage form and shape are applicable to the compositions that contains or do not contain additive; Can be good with the tremulous pulse approach through various administrations, directly be placed as the best in the tumor body.Picking dosage form of the present invention is the implantation slow release agent that bio-capacitivity, degradable absorb, and can make different shape because of the clinical needs of difference.The packing method of its Main Ingredients and Appearance and step in United States Patent (USP) (US5651986) have a detailed description, comprise the some kinds of methods that prepare slow releasing preparation: as, but be not limited to, (i) carrier holder powder and medicament mixed be pressed into implant then, promptly so-called mixing method; (ii) carrier holder fusing, mix solid cooled then, promptly so-called fusion method mutually with medicine to be packaged; (iii) the carrier holder is dissolved in the solvent, medicine dissolution to be packaged or be scattered in the polymer solution, evaporating solvent then, the universe is dry, promptly so-called dissolution method; (iv) spray drying method; And (v) freeze-drying etc.Wherein dissolution method can be used for the manufacturing of microsphere, and its method is arbitrarily, and anticancer pharmaceutical composition also can be packed in the liposome.
Wherein dissolution method can be used for the manufacturing of microsphere, and its method is arbitrarily, and entity-tumor-resistant medicine composition also can be packed in the liposome.
The characteristics of entity-tumor-resistant medicine composition technology of preparing of the present invention be with vasoinhibitor and cancer therapy drug separately or packaged in combination in pharmaceutic adjuvant, proportionally with active ingredient and pharmaceutic adjuvant dissolving, wait to fill part mixing after the universe dry.Treat that the universe is shaped immediately after dry and sterilizes packing.
Above vasoinhibitor can be in various degree inhibition or reduce the activity of tumor cell revascularization, experiment in vivo and vitro of the present invention is found the notable synergistic effect of vasoinhibitor to cancer therapy drug.When the two associating topical application, especially local the placement not only can overcome the toxic reaction that the whole body administration brings, and solved the tumor by local drug level and cross the low and cell sensitive question to medicine.
By following test and embodiment the technology side of composition for treating solid tumor of the present invention is further described:
Tumor-inhibiting action in the body of test one, vasoinhibitor and cancer therapy drug.
With the rat is subjects, with 2 * 10
5Individual tumor cell subcutaneous injection is in its hypochondrium, treats that tumor growth after 14 days is divided into it following 10 groups (seeing Table 1).First group is contrast, and the 2nd to 10 group is the treatment group, and wherein, the 2nd group is imatinib mesylate (IMTN), and the 3rd to 6 group is respectively Chlorambucil, cyclophosphamide, ifosfamide and melphalan.The the 7th to 10 group of associating that is respectively IMTN and Chlorambucil, cyclophosphamide, ifosfamide and melphalan.Except that IMTN placed in tumor, Chlorambucil, cyclophosphamide, ifosfamide and melphalan were intraperitoneal administration.Dosage measuring is 5mg/kg except that IMTI is 100mg/g.The treatment back was measured gross tumor volume size, relatively therapeutic effect (seeing Table 1) on the 30th day.
Table 1
| Test group (n) | Suffered treatment | Gross tumor volume (cm 3) | The P value |
| 1(6) | Contrast | 62±16cm 3 | |
| 2(6) | IMTI | 42±10cm 3 | ＜0.05 |
| 3(6) | Chlorambucil | 40±10cm 3 | ＜0.01 |
| 4(6) | Cyclophosphamide | 42±10cm 3 | ＜0.01 |
| 5(6) | Ifosfamide | 36±10cm 3 | ＜0.01 |
| 6(6) | Melphalan | 38±8cm 3 | ＜0.01 |
| 7(6) | The IMTN+ Chlorambucil | 26±6cm 3 | ＜0.001 |
| 8(6) | The IMTN+ cyclophosphamide | 24±46cm 3 | ＜0.001 |
| 9(6) | The IMTN+ ifosfamide | 20±6cm 3 | ＜0.001 |
| 10(6) | The IMTN+ melphalan | 16±3.2cm 3 | ＜0.001 |
Annotate: imatinib mesylate (IMTN) is a vasoinhibitor, and Chlorambucil, cyclophosphamide, ifosfamide and melphalan are the dichloro ethamine kind cancer therapy drug.The result shows, compares with matched group, and vasoinhibitor (the 2nd group) and dichloro ethamine kind cancer therapy drug (the 3rd to 6 group) application separately all have obvious tumor-inhibiting action (P＜0.05).And use in conjunction (the 7th to 10 group) has obvious synergistic effect (P＜0.001).
Tumor-inhibiting action in the body of test two, vasoinhibitor and cancer therapy drug.
With the rat is subjects, with 2 * 10
5Individual tumor cell subcutaneous injection is in its hypochondrium, treats that tumor growth after 14 days is divided into it following 10 groups (seeing Table 2).The 1st group is contrast, and the 2nd to 10 group is the treatment group, and wherein, the 2nd group is angiogenic inhibitor thalidomide; The the 3rd to 6 group is cancer therapy drug.The the 7th to 10 group of associating that is respectively angiogenic inhibitor thalidomide and different cancer therapy drugs.Except that angiogenic inhibitor thalidomide was placed in tumor, paclitaxel, docetaxel, hexamethylmelamine, letrozole were intraperitoneal administration.The dosage measuring angiogenic inhibitor thalidomide is that 200mg/kg is 5mg/kg outward.The treatment back was measured gross tumor volume size, relatively therapeutic effect (seeing Table 2) on the 30th day.
Table 2
| Test group (n) | Suffered treatment | Gross tumor volume (cm 3) | The P value |
| 1(6) | Contrast | 76±20cm 3 | |
| 2(6) | Thalidomide | 64±5.0cm 3 | ＜0.05 |
| 3(6) | Paclitaxel | 42±2.3cm 3 | ＜0.01 |
| 4(6) | Docetaxel | 46±3.6cm 3 | ＜0.01 |
| 5(6) | Hexamethylmelamine | 46±3.4cm 3 | ＜0.01 |
| 6(6) | Letrozole | 40±3.8cm 3 | ＜0.01 |
| 7(6) | Thalidomide ± paclitaxel | 26±3.6cm 3 | ＜0.001 |
| 8(6) | Thalidomide+docetaxel | 24±3.4cm 3 | ＜0.001 |
| 9(6) | Thalidomide+hexamethylmelamine | 22±3.2cm 3 | ＜0.001 |
| 10(6) | Thalidomide+letrozole | 22±3.0cm 3 | ＜0.001 |
Annotate: thalidomide is a vasoinhibitor, and paclitaxel and docetaxel are the representative of paclitaxel kind anti-cancer drugs thing, and hexamethylmelamine and letrozole are the representative of dichloro ethamine kind cancer therapy drug.
Test three, topical application vasoinhibitor are to the potentiation of antibiotic kind anti-cancer drugs thing.
With the rat is subjects, with 2 * 10
5Individual tumor cell subcutaneous injection is in its hypochondrium, treats that tumor growth after 14 days is divided into it following 10 groups (seeing Table 3).First group is contrast, and the 2nd to 10 group is the treatment group, and wherein, the 2nd group is 3,3-two chloro-5-(4-sulfonyloxy methyl yl pyridines)-2-dihydroindole ketone (DCM), and the 3rd to 6 group is respectively aclarubicin, amycin, epirubicin and pirarubicin.The the 7th to 10 group of associating that is respectively DCM and aclarubicin, amycin, epirubicin or pirarubicin.All medicines are placed in being tumor, and metering all is 5mg/kg except that blood vessel inhibitor DCM the 100mg/kg.The treatment back was measured gross tumor volume size, relatively therapeutic effect (seeing Table 3) on the 30th day.
Table 3
| Test group (n) | Suffered treatment | Gross tumor volume (cm 3) | The P value |
| 1(6) | Contrast | 58±12cm 3 | |
| 2(6) | DCM | 44±10cm 3 | ＜0.05 |
| 3(6) | Aclarubicin | 42±12cm 3 | ＜0.01 |
| 4(6) | Amycin | 36±8cm 3 | ＜0.01 |
| 5(6) | Epirubicin | 38±8cm 3 | ＜0.01 |
| 6(6) | Pirarubicin | 34±8cm 3 | ＜0.01 |
| 7(6) | The DCM+ aclarubicin | 24±4.6cm 3 | ＜0.001 |
| 8(6) | The LNM+ amycin | 24±4.4cm 3 | ＜0.001 |
| 9(6) | The LNM+ epirubicin | 20±4cm 3 | ＜0.001 |
| 10(6) | The LNM+ pirarubicin | 22±3.8cm 3 | ＜0.001 |
Annotate: 3, (4-sulfonyloxy methyl yl pyridines)-2-dihydroindole ketone (DCM) is a vasoinhibitor to 3-two chloro-5-, and aclarubicin, amycin, epirubicin and pirarubicin are the antibiotics cancer therapy drug.The result shows, compares with matched group, and vasoinhibitor (the 2nd group) and antibiotics cancer therapy drug (the 3rd to 6 group) application separately all have certain tumor-inhibiting action (P＜0.05).Yet use in conjunction (the 7th to 10 group) has obvious synergistic effect (P＜0.001).
Tumor-inhibiting action in the body of test four, vasoinhibitor and antibiotics cancer therapy drug.
With the rat is subjects, with 2 * 10
5Individual tumor cell subcutaneous injection is in its hypochondrium, treats that tumor growth after 14 days is divided into it following 10 groups (seeing Table 4).First group is contrast, the the 2nd to 10 group is the treatment group, wherein, the 2nd group is that (3H-narrows azoles-4-yl)-first-(Z)-Ya Neiweng-5-methoxy-1 to vasoinhibitor 3-[1-, 3-dihydro-indole-2-dihydroindole ketone (SU9516), the 3rd to 6 group is respectively Valrubicin, ametycin, losoxantrone, mitoxantrone.The the 7th to 10 group of associating that is respectively SU9516 and Valrubicin, ametycin, losoxantrone or mitoxantrone.Except that SU9516 placed in tumor, Valrubicin, ametycin, losoxantrone, mitoxantrone were intraperitoneal administration.Dosage measuring is 5mg/kg except that SU9516 is 100mg/kg.The treatment back was measured gross tumor volume size, relatively therapeutic effect (seeing Table 4) on the 30th day.
Table 4
| Test group (n) | Suffered treatment | Gross tumor volume (cm 3) | The P value |
| 1(6) | Contrast | 62±16cm 3 | |
| 2(6) | SU9516 | 40±9cm 3 | ＜0.05 |
| 3(6) | Valrubicin | 42±12cm 3 | ＜0.01 |
| 4(6) | Ametycin | 44±10cm 3 | ＜0.01 |
| 5(6) | Losoxantrone | 36±10cm 3 | ＜0.01 |
| 6(6) | Mitoxantrone | 40±8cm 3 | ＜0.01 |
| 7(6) | The SU9516+ Valrubicin | 24±6cm 3 | ＜0.001 |
| 8(6) | The SU9516+ ametycin | 22±46cm 3 | ＜0.001 |
| 9(6) | The SU9516+ losoxantrone | 24±6cm 3 | ＜0.001 |
| 10(6) | The SU9516+ mitoxantrone | 22±3.2cm 3 | ＜0.001 |
Annotate: SU9516 is that (3H-imidazoles-4-yl)-first-(Z)-Ya Neiweng-5-methoxy-1,3-dihydro-indole-the 2-dihydroindole ketone is a vasoinhibitor to 3-[1-, and Valrubicin, ametycin, losoxantrone and mitoxantrone are the antibiotics cancer therapy drug.The result shows, compares with matched group, and vasoinhibitor (the 2nd group) and antibiotics cancer therapy drug (the 3rd to 6 group) application separately all have obvious tumor-inhibiting action (P＜0.05).And use in conjunction (the 7th to 10 group) has obvious synergistic effect (P＜0.001).
Tumor-inhibiting action in the body of test five, vasoinhibitor and anti-metabolism cancer therapy drug.
With the rat is subjects, with 2 * 10
5Individual tumor cell subcutaneous injection is in its hypochondrium, treats that tumor growth after 14 days is divided into it following 10 groups (seeing Table 5).The 1st group is contrast, and the 2nd to 10 group is the treatment group, and wherein, the 2nd group is vasoinhibitor 1H-pyrroles-3-propanoic acid, 2-[(1,2-dihydro-2-oxygen-3H-indole-3-subunit) methyl]-4-methyl (SU6663); The the 3rd to 6 group is respectively the antimetabolic anticarcinoma agent thing.The the 7th to 10 group of associating that is respectively vasoinhibitor SU6663 and different antimetabolic anticarcinoma agent things.Except that blood vessel inhibitor SU6663 placed in tumor, 5-FU, pemetrexed, Rumi Qu Sai and methotrexate were intraperitoneal administration.Dosage measuring vasoinhibitor SU6663 is that 200mg/kg is 5mg/kg outward.The treatment back was measured gross tumor volume size, relatively therapeutic effect (seeing Table 5) on the 30th day.
Table 5
| Test group (n) | Suffered treatment | Gross tumor volume (cm 3) | The P value |
| 1(6) | Contrast | 74±23cm 3 | |
| 2(6) | SU6663 | 62±5.2cm 3 | ＜0.05 |
| 3(6) | 5-FU | 44±2.3cm 3 | ＜0.01 |
| 4(6) | Pemetrexed | 42±3.6cm 3 | ＜0.01 |
| 5(6) | Rumi Qu Sai | 44±3.4cm 3 | ＜0.01 |
| 6(6) | Methotrexate | 44±3.8cm 3 | ＜0.01 |
| 7(6) | SU6663+5-FU | 26±3.6cm 3 | ＜0.001 |
| 8(6) | The SU6663+ pemetrexed | 24±3.4cm 3 | ＜0.001 |
| 9(6) | SU6663+ Rumi Qu Sai | 20±3.2cm 3 | ＜0.001 |
| 10(6) | The SU6663+ methotrexate | 16±3.0cm 3 | ＜0.001 |
Annotate: 1H-pyrroles-3-propanoic acid, 2-[(1,2-dihydro-2-oxygen-3H-indole-3-subunit) methyl]-4-methyl (SU6663) is a vasoinhibitor, and 5-FU, pemetrexed, Rumi Qu Sai and methotrexate are the anti-metabolism cancer therapy drug.
Tumor-inhibiting action in the body of test six, vasoinhibitor and anti-metabolism cancer therapy drug.
With the rat is subjects, with 2 * 10
5Individual tumor cell subcutaneous injection is in its hypochondrium, treats that tumor growth after 14 days is divided into it following 10 groups (seeing Table 6).The 1st group is contrast, and the 2nd to 10 group is the treatment group, and wherein, the 2nd group is vasoinhibitor 2H-indole-2-dihydroindole ketone or 3-((4,5-dimethyl-1H-pyrroles-2-yl) methylene)-1, and 3-dihydro-[CAS] (SU5614); The the 3rd to 6 group is respectively the anti-metabolism cancer therapy drug.The the 7th to 10 group of associating that is respectively vasoinhibitor SU5614 and different anti-metabolism cancer therapy drugs.Except that blood vessel inhibitor SU5614 placed in tumor, carmofur, ftorafur, gemcitabine and Raltitrexed were intraperitoneal administration.Dosage measuring vasoinhibitor SU5614 is that 200mg/kg is 5mg/kg outward.The treatment back was measured gross tumor volume size, relatively therapeutic effect (seeing Table 6) on the 30th day.
Table 6
| Test group (n) | Suffered treatment | Gross tumor volume (cm 3) | The P value |
| 1(6) | Contrast | 72±20cm 3 | |
| 2(6) | SU5614 | 60±5.0cm 3 | ＜0.05 |
| 3(6) | Carmofur | 44±2.3cm 3 | ＜0.01 |
| 4(6) | Ftorafur | 46±3.6cm 3 | ＜0.01 |
| 5(6) | Gemcitabine | 42±3.4cm 3 | ＜0.01 |
| 6(6) | Raltitrexed | 40±3.8cm 3 | ＜0.01 |
| 7(6) | The SU5614+ carmofur | 28±3.6cm 3 | ＜0.001 |
| 8(6) | The SU5614+ ftorafur | 20±3.4cm 3 | ＜0.001 |
| 9(6) | The SU5614+ gemcitabine | 22±3.2cm 3 | ＜0.001 |
| 10(6) | The SU5614+ Raltitrexed | 18±3.0cm 3 | ＜0.001 |
Annotate: 2H-indole-2-dihydroindole ketone or 3-((4,5-dimethyl-1H-pyrroles-2-yl) methylene)-1,3-dihydro-[CAS] is vasoinhibitor (SU5614), and carmofur, ftorafur, gemcitabine and Raltitrexed are the anti-metabolism cancer therapy drug.
Similar potentiation also sees the associating of other vasoinhibitor and other nitrosourea cancer therapy drug.With multiple other tumor cell (comprising the cerebral tumor (CNS-1, C6,9L), gastric gland epithelial cancer (SA), bone tumor (BC), breast carcinoma (BA), papillary adenocarcinoma of thyroid (PAT), hepatocarcinoma, cancer of pancreas, renal carcinoma and the esophageal carcinoma etc.) is that subjects draws similar results.
In a word, experimental result shows that vasoinhibitor among the present invention is to the potentiation of listed anti-metabolism cancer therapy drug.Therefore, the effective ingredient of anticancer compound of the present invention is the associating of any one (or multiple) vasoinhibitor and any one (or multiple) anti-metabolism cancer therapy drug or packs separately.The entity-tumor-resistant medicine composition that contains above effective ingredient can be made into any dosage form or shape, but serves as preferred with the agent for slow releasing type.
The preparation method of entity-tumor-resistant medicine composition of the present invention is as follows:
1. the pharmaceutic adjuvant of weighing is put into container, add the certain amount of organic solvent dissolving evenly, the not strict qualification of the amount of organic solvent, suitable fully to be dissolved as.
2. adding the anticancer active ingredient of weighing shakes up again.The usage ratio of anticancer active ingredient and pharmaceutic adjuvant is decided because of specific requirement.
3. removal organic solvent.Vacuum drying, spraying or cold drying all can.
4. dried solid composite is made different shape as required.Also can be with straight forming behind adjuvant and the anticancer active ingredient mixing.
5. ray sterilizing (roentgendosis is different because of volume) is standby after the packing.Also available other method sterilization.
(4) specific embodiment
Embodiment 1.
With 80mg molecular weight peak value is that the polylactic acid (PLGA) of 15000-25000 is put into container, adds 100 milliliters of dichloromethane, behind the dissolving mixing, adds 10mg imatinib and 10mg melphalan, shakes up the dry organic solvent of removing of final vacuum again.Dried solid composite is shaped immediately, and ray sterilizing after the packing must contain the entity-tumor-resistant medicine composition of 10% imatinib and 10% melphalan.All be weight percentage.The drug release time of this entity-tumor-resistant medicine composition in external normal saline is 14-21 days, is 25-45 days at the subcutaneous drug release time of mice.
Embodiment 2. is as described in the embodiment 1, and anticancer effective component that different is is one of following:
Percentage by weight is the NSC 609974 (CAT) of 1-60%; Thalidomide; LS-2616; En Jisi peptide booth; En Duosi peptide booth; imatinib mesylate; 5-[5-fluoro-2-oxygen-1; the 2-indoline-(3Z)-methylene]-2; 4-dimethyl-1H-pyrroles-3-carboxylic acid (2-diethylaminoethyl) amide; 3; 3-two chloro-5-(4-sulfonyloxy methyl yl pyridines)-2-dihydroindole ketone (DCM); 3-[1-(the 3H-imidazoles-4-yl)-first-(Z)-Ya Neiweng-5-methoxy-1; 3-dihydro-indole-2-dihydroindole ketone; 1H-pyrroles-3-propanoic acid; 2-[(1; 2-dihydro-2-oxygen-3H-indole-3-subunit) methyl]-the 4-methyl; 2H-indole-2-dihydroindole ketone; 3-((4; 5-dimethyl-1H-pyrroles-2-yl) methylene)-1; 3-dihydro-[CAS]; pyrroles's lactone dihydroindole ketone; the lactams dihydroindole ketone; 3-(4-dimethylamino-naphthal-1-methylene)-1; 3-dihydro-indole-2-dihydroindole ketone; 1; 3-dihydro-5; 6-dimethoxy-3-[(4-hydroxyphenyl) methylene)-2H-indole-2-dihydroindole ketone; 3-[5-methyl-2-(2-oxygen-1; 2-dihydro-indol-3-yl)-1H-pyrroles-3-methyl]-propanoic acid; 5-[(Z)-(5-chloro-2-oxygen-1; 2-dihydro-3H-indole-3-methylene) methyl]-N-(2-(diethylin) ethyl-1H-pyrroles-3-carboxylic acid amides; 5-[(Z)-(5-fluoro-2-oxygen-1; 2-dihydro-3H-indole-3-subunit) methyl]-2; 4-dimethyl-N-(2-pyrrolidinyl-1-ethyl)-1H-pyrroles-3-carboxylic acid amides; 5-[(Z)-(5-chloro-2-oxygen-1; 2-dihydro-3H-indole-3-subunit) methyl]-2; 4-dimethyl-N-(2-pyrrolidinyl-1-ethyl)-1H-pyrroles-3-carboxylic acid amides; 3-[[3-phenyl-4 (3H)-quinazolinone-2-methyl) TGA] hydrazono-]-1H-2-dihydroindole ketone (SU1165); 3-two (4-anisyl) methylene-2-dihydroindole ketone; the 3-[4-formyl piperazine-4yl)-benzal]-the 2-dihydroindole ketone; 3-([5-imidazoles] 2; 1-methylene thiazole)-the 2-dihydroindole ketone; 3-1 (2; 6-methylimidazole [2; methylene-5-methoxyl group-2-the dihydroindole ketone of 1-Bj-thiazole-5-yl); imidazoles [2; 1-b] methylene thiazole-2-dihydroindole ketone; methylene indole-2-dihydroindole ketone; (2-chloro-indole) methylene-2-dihydroindole ketone; arlydene 2-dihydroindole ketone; 1; 3-dihydro-5; 6-dimethoxy-3-[(4-hydroxyphenyl) methylene)-2H-indole-2-dihydroindole ketone; 3-(4-dimethylamino-benzal)-2-dihydroindole ketone; 5-chloro-3-methylene pyridine-2-dihydroindole ketone; 3; 3-lutidines-1-phenyl-2-dihydroindole ketone; gefitinib; Erlotinib; phenol; 4-(4-(((1R)-1-phenethyl) amino)-1H-pyrrolo-(2; 3-d) pyrimidine-6-base; Lapatinib; ZK-222584; WAY-EKB 569 or E-3-(2-chloro-3-methylene indole) 1, the Chlorambucil of 3-indoline-2-dihydroindole ketone and 1-30%; cyclophosphamide; ifosfamide; melphalan; 4H-peroxide cyclophosphamide; methoxymerphalan; hexamethylmelamine; letrozole; cantharidin; the combination of norcantharidin or Ah bundle's TEPA.
Embodiment 3.
With 70mg molecular weight peak value is that the polylactic acid (PLGA) of 25000-35000 is put into container, after adding 100 milliliters of dichloromethane dissolving mixings, add 20mg 5-[5-fluoro-2-oxygen-1, the 2-indoline-(3Z)-methylene]-2,4-dimethyl-1H-pyrroles-3-carboxylic acid (2-diethylaminoethyl) amide (SU11248) and 10 milligrams of paclitaxels shake up the dry organic solvent of removing of final vacuum again.Dried solid composite is shaped immediately, and ray sterilizing after the packing must contain the entity-tumor-resistant medicine composition of 20%SU11248 and 10% paclitaxel.All be weight percentage.The drug release time of this entity-tumor-resistant medicine composition in external normal saline is 15-20 days, is 30-40 days at the subcutaneous drug release time of mice.
Embodiment 4. is as described in the embodiment 3, and different is that contained anticancer effective component is:
The NSC 609974 of 1-50%; thalidomide; LS-2616; En Jisi peptide booth; En Duosi peptide booth; the vascular endothelial growth factor receptor inhibitor; imatinib mesylate; 5-[5-fluoro-2-oxygen-1; the 2-indoline-(3Z)-methylene]-2; 4-dimethyl-1H-pyrroles-3-carboxylic acid (2-diethylaminoethyl) amide; 3; 3-two chloro-5-(4-sulfonyloxy methyl yl pyridines)-2-dihydroindole ketone (DCM); 3[1-(the 3H-imidazoles-4-yl)-first-(Z)-Ya Neiweng-5-methoxy-1; 3-dihydro-indole-2-dihydroindole ketone; 1H-pyrroles-3-propanoic acid; 2-[1; 2-dihydro-2-oxygen-3H-indole-3-subunit) methyl]-the 4-methyl; the 2H-indol-2-one; 3-((4; 5-dimethyl-1H-pyrroles-2-yl) methylene)-1; 3-dihydro-[CAS]; gefitinib; Erlotinib; phenol; 4-(4-(((1R)-1-phenethyl) amino)-1H-pyrrolo-(2,3-d) pyrimidine-6-base; Lapatinib; ZK-222584 or WAY-EKB 569 and 1-50% paclitaxel; docetaxel; 2 '-hydroxyl taxol; 10-removes the acetyl Baccatine III; 14 beta-hydroxies-10-removes the acetyl Baccatine III; 9-dihydro-13-Baccatine III; 10-goes the combination of acetyl taxol or 7-table-taxol.Below all be weight percentage.
Embodiment 5.
60mg polifeprosan (to carboxy phenyl propane: certain herbaceous plants with big flowers diacid weight ratio is 80: 20) copolymer is put into container, add 100 milliliters of dichloromethane dissolving mixings after, add 20mg thalidomide and 20mg amycin, shake up the dry organic solvent of removing of final vacuum again.Dried solid composite is shaped immediately, and ray sterilizing after the packing must contain 20% thalidomide and 20% amycin entity-tumor-resistant medicine composition.All be weight percentage.The drug release time of this entity-tumor-resistant medicine composition in external normal saline is 15-20 days, is 30-40 days at the subcutaneous drug release time of mice.
Embodiment 6. is as described in the embodiment 5, and different is that anticancer effective component is:
The NSC 609974 of percentage by weight 1-50%; thalidomide; LS-2616; En Jisi peptide booth; En Duosi peptide booth; the vascular endothelial growth factor receptor inhibitor; imatinib mesylate; 5-[5-fluoro-2-oxygen-1; the 2-indoline-(3Z)-methylene]-2; 4-dimethyl-1H-pyrroles 3-carboxylic acid (2-diethylaminoethyl) amide; 3; 3-two chloro-5-(4-sulfonyloxy methyl yl pyridines)-2-dihydroindole ketone (DCM); 3-[1-(the 3H-imidazoles-4-yl)-first-(Z)-Ya Neiweng-5-methoxy-1; 3-dihydro-indole-2-dihydroindole ketone; 1H-pyrroles-3-propanoic acid; 2-[(1; 2-dihydro-2-oxygen-3H-indole-3-subunit) methyl]-the 4-methyl; the 2H-indol-2-one; 3-((4; 5-dimethyl-1H-pyrroles-2-yl) methylene)-1; 3-dihydro-[CAS]; gefitinib; Erlotinib; phenol; 4-(4-(((1R)-1-phenethyl) amino)-1H-pyrrolo-(2,3-d) pyrimidine-6-base; Lapatinib; ZK-222584 or WAY-EKB 569 and 1-50% bleomycin; daunomycin; aclarubicin; amycin; epirubicin; pirarubicin; Valrubicin; ametycin; actinomycin D; losoxantrone; mitoxantrone; piroxantrone; the combination of teloxantrone or chlorine assistant star.
Embodiment 7.
60mg polifeprosan (to carboxy phenyl propane: certain herbaceous plants with big flowers diacid weight ratio is 80: 20) copolymer is put into container, after adding 100 milliliters of dichloromethane dissolving mixings, add 30mg imatinib mesylate and 10 milligrams of 5-FU, shake up the dry organic solvent of removing of final vacuum again.Dried solid composite is shaped immediately, and ray sterilizing after the packing must contain 30% imatinib mesylate and 10%5-FU entity-tumor-resistant medicine composition.All be weight percentage.The drug release time of this entity-tumor-resistant medicine composition in external normal saline is 15-20 days, is 30-40 days at the subcutaneous drug release time of mice.
Embodiment 8. is as described in the embodiment 7, and different is that anticancer effective component is:
The NSC 609974 of 1-50%; thalidomide; LS-2616; En Jisi peptide booth; En Duosi peptide booth; the vascular endothelial growth factor receptor inhibitor; imatinib mesylate; 5-[5-fluoro-2-oxygen-1; 2-indoline (3Z) methylene] 2; 4-dimethyl-1H-pyrroles-3-carboxylic acid (2-diethylaminoethyl) amide; 3; 3-two chloro-5-(4-sulfonyloxy methyl yl pyridines)-2-dihydroindole ketone (DCM); 3[1-(the 3H-imidazoles-4-yl)-first-(Z)-Ya Neiweng-5-methoxy-1; 3-dihydro-indole-2-dihydroindole ketone; 1H-pyrroles-3-propanoic acid; 2-[(1; 2-dihydro-2-oxygen-3H-indole-3-subunit) methyl]-the 4-methyl; the 2H-indol-2-one; 3-((4; 5-dimethyl-1H-pyrroles-2-yl) methylene)-1; 3-dihydro-[CAS]; gefitinib; Erlotinib; phenol; 4-(4-(((1R)-1-phenethyl) amino)-1H-pyrrolo-(2,3-d) pyrimidine-6-base; Lapatinib; the Ismipur of ZK-222584 or WAY-EKB 569 and 1-50%; 5-fluorouracil (5-FU); pemetrexed; pemetrexed disodium; Rumi Qu Sai; doxifluridine; floxuridine; mercaptopurine; thioguanine; methotrexate; carmofur; ftorafur; galocitabine; ibacitabine; enocitabine; ancitabine; decitabine; flurocitabine; enocitabine; his shore of imidazoles; GR 30921X; mitotane; cytosine arabinoside; hydroxyurea; the 5-fluorouracil nucleoside; capecitabine; gemcitabine; fludarabine; thunder accounts for for song; Raltitrexed; the atropic cytidine; dexrazoxane; the combination of cladribine or pentoside.Below all be weight percentage.
Embodiment 9.
(EVAc) puts into container with the 60mg ethylene vinyl acetate copolymer, adds 100 milliliters of dichloromethane, behind the dissolving mixing, adds 20mg imatinib mesylate and 20mg ametycin, shakes up the dry organic solvent of removing of final vacuum again.Dried solid composite is shaped immediately, and ray sterilizing after the packing must contain the entity-tumor-resistant medicine composition of 20% imatinib mesylate and 20% ametycin.The drug release time of this entity-tumor-resistant medicine composition in external normal saline is 15-20 days, is 30-40 days at the subcutaneous drug release time of mice.
Embodiment 10. is as described in embodiment 1,2 or 3, and different is, and that used pharmaceutic adjuvant is respectively is one of following:
A) molecular weight is the polylactic acid (PLA) of 5000-15000,10000-20000,20000-35000 or 30000-50000;
B) molecular weight is the glycolic of 5000-15000,10000-20000,20000-35000 or 30000-50000 and the copolymer of lactic acid (PLGA);
C) ethylene vinyl acetate;
D) weight ratio 10: 90,20: 80,30: 70,40: 60,50: 50 or 60: 40 to carboxy phenyl propane: certain herbaceous plants with big flowers diacid copolymer (polifeprosan); With
E) xylitol, oligosaccharide, chitin, potassium salt, sodium salt, protein, polysaccharide, hyaluronic acid, chondroitin sulfate, collagen protein, gelatin or albumin.
Embodiment 11. is as described in embodiment 1 or 3, and different is to contain anticancer effective component to be:
(a) combination of 10-30% imatinib mesylate, Erlotinib or thalidomide and 20% Chlorambucil, cyclophosphamide, ifosfamide, melphalan, 4H-peroxide cyclophosphamide, methoxymerphalan, hexamethylmelamine, letrozole, cantharidin, norcantharidin or Ah bundle's TEPA;
(b) combination of 10-30% imatinib mesylate, Erlotinib or thalidomide and 20% paclitaxel, Docetaxel (docetaxel) or 2 '-hydroxyl taxol;
(c) combination of 10-30% imatinib mesylate, Erlotinib or thalidomide and 20% bleomycin, daunomycin, aclarubicin, amycin, epirubicin, pirarubicin, Valrubicin, ametycin, actinomycin D, losoxantrone, mitoxantrone, piroxantrone, teloxantrone or chlorine assistant star; Or
(d) 10-30% imatinib mesylate, Erlotinib, or the Ismipur of thalidomide and 20%, 5-fluorouracil (5-FU), pemetrexed, pemetrexed disodium, Rumi Qu Sai, doxifluridine, floxuridine, mercaptopurine, thioguanine, methotrexate, carmofur, ftorafur, galocitabine, ibacitabine, enocitabine, ancitabine, decitabine, flurocitabine, enocitabine, his shore of imidazoles, GR 30921X, mitotane, cytosine arabinoside, hydroxyurea, the 5-fluorouracil nucleoside, capecitabine, gemcitabine, fludarabine, thunder accounts for for song, Raltitrexed, the atropic cytidine, dexrazoxane, the combination of cladribine or pentoside.Below all be weight percentage.
Embodiment 12. is as described in embodiment 1 or 3, and different is to contain anticancer effective component to be:
(a) 10-30% Chlorambucil, cyclophosphamide, ifosfamide, melphalan, 4H-peroxide cyclophosphamide, methoxymerphalan, hexamethylmelamine, letrozole, cantharidin, the NSC 609974 of norcantharidin or Ah bundle's TEPA and 10-30%, thalidomide, LS-2616, imatinib mesylate, 5-[5-fluoro-2-oxygen-1, the 2-indoline-(3Z)-methylene]-2,4-dimethyl-1H-pyrroles-3-carboxylic acid (2-diethylaminoethyl) amide, 3,3 two chloro-5-(4-sulfonyloxy methyl yl pyridines)-2-dihydroindole ketone (DCM), 3-[1-(the 3H-imidazoles-4-yl)-first-(Z)-Ya Neiweng-5-methoxy-1,3-dihydro-indole-2-dihydroindole ketone, 1H-pyrroles-3-propanoic acid, 2-[(1,2-dihydro-2-oxygen-3H-indole-3-subunit) methyl]-the 4-methyl, the 2H-indol-2-one, 3-((4,5-dimethyl-1H-pyrroles-2-yl) methylene)-1,3-dihydro-[CAS], gefitinib, Erlotinib, phenol, 4-(4-(((1R)-1-phenethyl) amino)-1H-pyrrolo-(2,3-d) pyrimidine-6-base, Lapatinib, the combination of ZK-222584 or WAY-EKB 569;
(b) 10-30%5-fluorouracil, pemetrexed, pemetrexed disodium, Rumi Qu Sai, doxifluridine, floxuridine, mercaptopurine, thioguanine, methotrexate, carmofur, ftorafur, galocitabine, ibacitabine, enocitabine, ancitabine, decitabine, flurocitabine, enocitabine, his shore of imidazoles, GR 30921X, mitotane, cytosine arabinoside, hydroxyurea, the 5-fluorouracil nucleoside, capecitabine, gemcitabine, fludarabine, thunder accounts for for song, Raltitrexed, the atropic cytidine, dexrazoxane, the NSC 609974 of cladribine or pentoside and 10-30%, thalidomide, LS-2616, imatinib mesylate, 5-[5 fluoro-2-oxygen-1, the 2-indoline-(3Z)-methylene]-2,4-dimethyl-1H-pyrroles-3-carboxylic acid (2-diethylaminoethyl) amide, 3,3-two chloro-5-(4-sulfonyloxy methyl yl pyridines)-2-dihydroindole ketone (DCM), 3-[1-(the 3H-imidazoles-4-yl)-first-(Z)-Ya Neiweng-5-methoxy-1,3-dihydro-indole-2-dihydroindole ketone, 1H-pyrroles-3-propanoic acid, 2-[(1,2-dihydro-2-oxygen-3H-indole-3-subunit) methyl]-the 4-methyl, the 2H-indol-2-one, 3-((4,5-dimethyl-1H-pyrroles-2-yl) methylene)-1,3-dihydro-[CAS], gefitinib, Erlotinib, phenol, 4-(4-(((1R)-1-phenethyl) amino)-1H-pyrrolo-(2,3-d) pyrimidine-6-base, Lapatinib, the combination of ZK-222584 or WAY-EKB 569;
(c) 10-30% paclitaxel, the NSC 609974 of Docetaxel (docetaxel) or 2 '-hydroxyl taxol and 10-30%, thalidomide, LS-2616, imatinib mesylate, 5-[5-fluoro-2-oxygen-1, the 2-indoline-(3Z)-methylene]-2,4-dimethyl-1H-pyrroles-3-carboxylic acid (2-diethylaminoethyl) amide, 3,3-two chloro-5-(4-sulfonyloxy methyl yl pyridines)-2-dihydroindole ketone (DCM), 3-[1-(the 3H-imidazoles-4-yl)-first-(Z)-Ya Neiweng-5-methoxy-1,3-dihydro-indole-2-dihydroindole ketone, 1H-pyrroles-3-propanoic acid, 2-[(1,2-dihydro-2-oxygen-3H-indole-3-subunit) methyl]-the 4-methyl, the 2H-indol-2-one, 3-((4,5-dimethyl-1H-pyrroles-2-yl) methylene)-1,3-dihydro-[CAS], gefitinib, Erlotinib, phenol, 4-(4-(((1R)-1-phenethyl) amino)-1H-pyrrolo-(2,3-d) pyrimidine-6-base, Lapatinib, the combination of ZK-222584 or WAY-EKB 569; Or
(d) 10-30% bleomycin; daunomycin; aclarubicin; amycin; epirubicin; pirarubicin; Valrubicin; ametycin; actinomycin D; losoxantrone; mitoxantrone; piroxantrone; the NSC 609974 of teloxantrone or chlorine assistant star and 10-30%; thalidomide; LS-2616; imatinib mesylate; 5-[5-fluoro-2-oxygen-1; the 2-indoline-(3Z)-methylene]-2; 4-dimethyl-1H-pyrroles-3-carboxylic acid (2-diethylaminoethyl) amide; 3; 3-two chloro-5-(4-sulfonyloxy methyl yl pyridines)-2-dihydroindole ketone (DCM); 3-[1-(the 3H-imidazoles-4-yl)-first-(Z)-Ya Neiweng-5-methoxy-1; 3-dihydro-indole-2-dihydroindole ketone; 1H-pyrroles-3-propanoic acid; 2-[(1; 2-dihydro-2-oxygen-3H-indole-3-subunit) methyl]-the 4-methyl; the 2H-indol-2-one; 3-((4; 5-dimethyl-1H-pyrroles-2-yl) methylene)-1; 3-dihydro-[CAS]; gefitinib; Erlotinib; phenol; 4-(4-(((1R)-1-phenethyl) amino)-1H-pyrrolo-(2,3-d) pyrimidine-6-base; Lapatinib; the combination of ZK-222584 or WAY-EKB 569.Below all be weight percentage.
Test seven, anti-cancer composition are to tumor vascular inhibitory action
With the rat is subjects, with 21 * 10
5Individual tumor cell subcutaneous injection treats that in its hypochondrium tumor growth was divided into 10 groups with it after 14 days.First group is contrast, and the 2nd to 9 group is the treatment group, 10 kinds of tumors pharmaceutical combinations accepting respectively to mention among the embodiment 11.All medicines are placed in being tumor, and the amount of pharmaceutical composition is 0.25mg.The treatment back was taken out tumor on the 10th day, observed blood vessel through H.E. dyeing and suppressed situation, and calculate tumor vascular suppression ratio (%).
The result shows that the different pharmaceutical that tries has the obvious suppression effect to tumor vessel, and suppression ratio is between 44%-80%.Show that the used tumor vessel inhibitor of the present invention is of universal significance.Therefore, the tumor vessel selection of inhibitors in the composition for treating solid tumor of the present invention is for arbitrarily.Equally, the associating of cancer therapy drug and tumor vessel inhibitor also is arbitrarily.
Composition for treating solid tumor can be made various dosage forms with existing method.Above embodiment only is used for explanation, and also unrestricted application of the present invention.
Claims (10)
1. anticancer pharmaceutical composition, comprise anticancer effective component and pharmaceutic adjuvant, it is characterized in that anticancer effective component is the combination of vasoinhibitor and cancer therapy drug, described cancer therapy drug is to have the medicine that suppresses growth of tumour cell, is selected from one of dichloro ethamine kind drug (bischloroethylamines), paclitaxel kind anti-cancer drugs thing (taxanes), antitumor antibiotics class medicine or antimetabolitas or combination.
2. the anticancer pharmaceutical composition according to claim 1; it is characterized in that described vasoinhibitor is a NSC 609974; Thalidomide; LS-2616; En Jisi peptide booth; En Duosi peptide booth; imatinib mesylate; 5-[5-fluoro-2-oxygen-1; 2 indoline-(3Z)-methylene]-2; 4-dimethyl-1H-pyrroles-3-carboxylic acid (2-diethylaminoethyl) amide; 3; 3-two chloro-5-(4-sulfonyloxy methyl yl pyridines)-2-dihydroindole ketone (DCM); 3-[1-(the 3H-imidazoles-4-yl)-first-(Z)-Ya Neiweng-5-methoxy-1; 3-dihydro-indole-2-dihydroindole ketone; 1H-pyrroles-3-propanoic acid; 2-[(1; 2-dihydro-2-oxygen-3H-indole-3-subunit) methyl]-the 4-methyl; 2H-indole-2-dihydroindole ketone; 3-((4; 5-dimethyl-1H-pyrroles-2-yl) methylene)-1; 3-dihydro-[CAS]; pyrroles's lactone dihydroindole ketone; the lactams dihydroindole ketone; 3-(4-dimethylamino-naphthal-1-methylene)-1; 3-dihydro-indole-2-dihydroindole ketone; 1; 3-dihydro-5; 6-dimethoxy-3-[(4-hydroxyphenyl) methylene)-2H-indole-2-dihydroindole ketone; 3-[5-methyl-2-(2-oxygen-1; 2-dihydro-indol-3-yl)-1H-pyrroles-3-methyl]-propanoic acid; 5-[(Z)-(5-chloro-2-oxygen-1; 2-dihydro-3H-indole-3-methylene) methyl]-N-(2-(diethylin) ethyl-1H-pyrroles-3-carboxylic acid amides; 5-[(Z)-(5-fluoro-2-oxygen-1; 2-dihydro-3H-indole-3-subunit) methyl]-2; 4-dimethyl-N-(2-pyrrolidinyl-1-ethyl)-1H-pyrroles-3-carboxylic acid amides; 5-[(Z)-(5-chloro-2-oxygen-1; 2-dihydro-3H-indole-3-subunit) methyl]-2; 4-dimethyl-N-(2-pyrrolidinyl-1-ethyl)-1H-pyrroles-3-carboxylic acid amides; 3-[[3-phenyl-4 (3H)-quinazolinone-2-methyl) TGA] hydrazono-]-1H-2-dihydroindole ketone (SU1165); 3-two (4-anisyl) methylene-2-dihydroindole ketone; the 3-[4-formyl piperazine-4yl)-benzal]-the 2-dihydroindole ketone; 3-([5-imidazoles] 2; 1-methylene thiazole)-the 2-dihydroindole ketone; 3-1 (2; 6-methylimidazole [2; methylene-5-methoxyl group-2-the dihydroindole ketone of 1-Bj-thiazole-5-yl); imidazoles [2; 1-b] methylene thiazole-2-dihydroindole ketone; methylene indole-2-dihydroindole ketone; (2-chloro-indole) methylene-2-dihydroindole ketone; arlydene 2-dihydroindole ketone; 1; 3-dihydro-5; 6-dimethoxy-3-[(4-hydroxyphenyl) methylene)-2H-indole-2-dihydroindole ketone; 3-(4-dimethylamino-benzal)-2-dihydroindole ketone; 5-chloro-3-methylene pyridine-2-dihydroindole ketone; 3; 3-lutidines-1-phenyl-2-dihydroindole ketone; gefitinib; Erlotinib; phenol; 4-(4-(((1R)-1-phenethyl) amino)-1H-pyrrolo-(2; 3-d) pyrimidine-6-base; Lapatinib; ZK-222584; WAY-EKB 569 and E-3-(2-chloro-3-methylene indole) 1, a kind of in 3-indoline-2-dihydroindole ketone or several.
3. the anticancer pharmaceutical composition according to claim 1 is characterized in that described dichloro ethamine kind cancer therapy drug
Be selected from Chlorambucil, cyclophosphamide, ifosfamide, melphalan, 4H-peroxide cyclophosphamide, methoxymerphalan, hexamethylmelamine, letrozole, cantharidin, norcantharidin or Ah bundle's TEPA.
4. the anticancer pharmaceutical composition according to claim 1 is characterized in that described paclitaxel kind anti-cancer drugs thing is selected from paclitaxel, docetaxel, 2 '-hydroxyl taxol, 10-and goes acetyl Baccatine III, 14 beta-hydroxies-10-to go acetyl Baccatine III, 9-dihydro-13-Baccatine III, 10-to remove acetyl taxol or 7-table-taxol.
5. the anticancer pharmaceutical composition according to claim 1 is characterized in that described antitumor antibiotics class medicine is selected from bleomycin, daunomycin, aclarubicin, amycin, epirubicin, pirarubicin, Valrubicin, ametycin, actinomycin D, losoxantrone, mitoxantrone, piroxantrone, teloxantrone or chlorine assistant star.
6. the anticancer pharmaceutical composition according to claim 1 is characterized in that described anti-metabolism cancer therapy drug is selected from 5-fluorouracil, pemetrexed, pemetrexed disodium, Rumi Qu Sai, doxifluridine, floxuridine, mercaptopurine, thioguanine, methotrexate, carmofur, ftorafur, galocitabine, ibacitabine, enocitabine, ancitabine, decitabine, flurocitabine, enocitabine, his shore of imidazoles, GR 30921X, mitotane, cytosine arabinoside, hydroxyurea, the 5-fluorouracil nucleoside, capecitabine, gemcitabine, fludarabine, thunder accounts for for song, Raltitrexed, the atropic cytidine, dexrazoxane, cladribine or pentoside;
Below all be weight percentage.
7. the anticancer pharmaceutical composition according to claim 1 is characterized in that effective ingredient is one of following:
(a) 10-30% Chlorambucil, cyclophosphamide, ifosfamide, melphalan, 4H-peroxide cyclophosphamide, methoxymerphalan, hexamethylmelamine, letrozole, cantharidin, the NSC 609974 of norcantharidin or Ah bundle's TEPA and 10-30%, thalidomide, LS-2616, imatinib mesylate, 5-[5-fluoro-2-oxygen-1, the 2-indoline-(3Z)-methylene]-2,4-dimethyl-1H-pyrroles-3-carboxylic acid (2-diethylaminoethyl) amide, 3,3-two chloro-5-(4-sulfonyloxy methyl yl pyridines)-2-dihydroindole ketone (DCM), 3-[1-(the 3H-imidazoles-4-yl)-first-(Z)-Ya Neiweng-5-methoxy-1,3-dihydro-indole-2-dihydroindole ketone, 1H-pyrroles-3-propanoic acid, 2-[(1,2-dihydro-2-oxygen-3H-indole-3-subunit) methyl]-the 4-methyl, the 2H-indol-2-one, 3-((4,5-dimethyl-1H-pyrroles-2-yl) methylene)-1,3-dihydro-[CAS], gefitinib, Erlotinib, phenol, 4-(4-(((1R)-1-phenethyl) amino)-1H-pyrrolo-(2,3-d) pyrimidine-6-base, Lapatinib, the combination of ZK-222584 or WAY-EKB 569;
(b) 10-30%5-fluorouracil, pemetrexed, pemetrexed disodium, Rumi Qu Sai, doxifluridine, floxuridine, mercaptopurine, thioguanine, methotrexate, carmofur, ftorafur, galocitabine, ibacitabine, enocitabine, ancitabine, decitabine, flurocitabine, enocitabine, his shore of imidazoles, GR 30921X, mitotane, cytosine arabinoside, hydroxyurea, the 5-fluorouracil nucleoside, capecitabine, gemcitabine, fludarabine, thunder accounts for for song, Raltitrexed, the atropic cytidine, dexrazoxane, the NSC 609974 of cladribine or pentoside and 10-30%, thalidomide, LS-2616, imatinib mesylate, 5-[5-fluoro-2-oxygen-1, the 2-indoline-(3Z)-methylene]-2,4-dimethyl-1H-pyrroles-3-carboxylic acid (2-diethylaminoethyl) amide, 3,3-two chloro-5-(4-sulfonyloxy methyl yl pyridines)-2-dihydroindole ketone (DCM), 3-[1-(the 3H-imidazoles-4-yl)-first-(Z)-Ya Neiweng-5-methoxy-1,3-dihydro-indole-2-dihydroindole ketone, 1H-pyrroles-3-propanoic acid, 2-[(1,2-dihydro-2-oxygen-3H-indole-3-subunit) methyl]-the 4-methyl, the 2H-indol-2-one, 3-((4,5-dimethyl-1H-pyrroles-2-yl) methylene)-1,3-dihydro-[CAS], gefitinib, Erlotinib, phenol, 4-(4-(((1R)-1-phenethyl) amino)-1H-pyrrolo-(2,3-d) pyrimidine-6-base, Lapatinib, the combination of ZK-222584 or WAY-EKB 569;
(c) 10-30% paclitaxel, the NSC 609974 of Docetaxel (docetaxel) or 2 '-hydroxyl taxol and 10-30%, thalidomide, LS-2616, imatinib mesylate, 5-[5-fluoro-2-oxygen-1, the 2-indoline-(3Z)-methylene]-2,4-dimethyl-1H-pyrroles-3-carboxylic acid (2-diethylaminoethyl) amide, 3,3-two chloro-5-(4-sulfonyloxy methyl yl pyridines)-2-dihydroindole ketone (DCM), 3-[1-(the 3H-imidazoles-4-yl)-first-(Z)-Ya Neiweng-5-methoxy-1,3-dihydro-indole-2-dihydroindole ketone, 1H-pyrroles-3-propanoic acid, 2-[(1,2-dihydro-2-oxygen-3H-indole-3-subunit) methyl]-the 4-methyl, the 2H-indol-2-one, 3-((4,5-dimethyl-1H-pyrroles-2-yl) methylene)-1,3-dihydro-[CAS], gefitinib, Erlotinib, phenol, 4-(4-(((1R)-1-phenethyl) amino)-1H-pyrrolo-(2,3-d) pyrimidine-6-base, Lapatinib, the combination of ZK-222584 or WAY-EKB 569; Or
(d) 10-30% bleomycin, daunomycin, aclarubicin, amycin, epirubicin, pirarubicin, Valrubicin, ametycin, actinomycin D, losoxantrone, mitoxantrone, piroxantrone, the NSC 609974 of teloxantrone or chlorine assistant star and 10-30%, thalidomide, LS-2616, imatinib mesylate, 5-[5-fluoro-2-oxygen-1, the 2-indoline-(3Z)-methylene]-2,4-dimethyl-1H-pyrroles-3-carboxylic acid (2-diethylaminoethyl) amide, 3,3-two chloro-5-(4-sulfonyloxy methyl yl pyridines)-2-dihydroindole ketone (DCM), 3-[1-(the 3H-imidazoles-4-yl)-first-(Z)-Ya Neiweng-5-methoxy-1,3-dihydro-indole-2-dihydroindole ketone, 1H-pyrroles-3-propanoic acid, 2-[(1,2-dihydro-2-oxygen-3H-indole-3-subunit) methyl]-the 4-methyl, the 2H-indol-2-one, 3-((4,5-dimethyl-1H-pyrroles-2-yl) methylene)-1,3-dihydro-[CAS], gefitinib, Erlotinib, phenol, 4-(4-(((1R)-1-phenethyl) amino)-1H-pyrrolo-(2,3-d) pyrimidine-6-base, Lapatinib, the combination of ZK-222584 or WAY-EKB 569;
Below all be weight percentage.
8. the anticancer pharmaceutical composition according to claim 1 is characterized in that, described pharmaceutic adjuvant is a kind of or its combination in macromolecule, sugar or the protein of the absorption of bio-capacitivity degradable; The macromolecule that described bio-capacitivity degradable absorbs be selected from polylactic acid, glycolic and lactic acid copolymer, ethylene vinyl acetate copolymer, polifeprosan, to the copolymer of carboxy phenyl propane and certain herbaceous plants with big flowers diacid with and composition thereof.
9. the entity-tumor-resistant medicine composition according to claim 1 is characterized in that this anti-cancer composition is injection, muddy suspension, ointment, capsule, slow releasing agent, implant or implantation slow release agent.
10. the application of the described entity-tumor-resistant medicine composition of claim 1 is used to prepare the medicine that treatment originates from cancer, sarcoma or the carcinosarcoma of people and animal brain, central nervous system, kidney, liver, gallbladder, incidence, oral cavity, thyroid, skin, mucosa, body of gland, blood vessel, osseous tissue, lymph node, lungs, esophagus, stomach, mammary gland, pancreas, eyes, nasopharynx part, uterus, ovary, endometrium, cervix uteri, prostate, bladder, colon or rectum former or secondary.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510044381 CN1733304A (en) | 2005-08-05 | 2005-08-05 | Anticancer medicine composition containing blood vessel inhibitor |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510044381 CN1733304A (en) | 2005-08-05 | 2005-08-05 | Anticancer medicine composition containing blood vessel inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1733304A true CN1733304A (en) | 2006-02-15 |
Family
ID=36076059
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200510044381 Pending CN1733304A (en) | 2005-08-05 | 2005-08-05 | Anticancer medicine composition containing blood vessel inhibitor |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1733304A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012079232A1 (en) * | 2010-12-15 | 2012-06-21 | Lai Hung-Cheng | Compounds used for treating cancer and the use thereof |
-
2005
- 2005-08-05 CN CN 200510044381 patent/CN1733304A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012079232A1 (en) * | 2010-12-15 | 2012-06-21 | Lai Hung-Cheng | Compounds used for treating cancer and the use thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100350974C (en) | Anticarcinogen composition | |
| CN1861055A (en) | Composite slow-releasing anticarcinogen injection contg. platinum compounds | |
| CN100500219C (en) | Anti tumour medicinal composition containing platinum compound | |
| CN1846672A (en) | Anticancer medicine composition containing antimetabolite | |
| CN1733304A (en) | Anticancer medicine composition containing blood vessel inhibitor | |
| CN1686545A (en) | Anti entity tumour medicinal composition | |
| CN100431606C (en) | Anti-cancer medicine composition | |
| CN1736486A (en) | Anticancer implantation agent | |
| CN1923173A (en) | Anti-cancer drugs slow release agent comprising anticancer antibiotics and booster thereof | |
| CN1686553A (en) | Anti entity tumour medicinal composition | |
| CN1857723A (en) | Slow released anticancer medicine preparation with both amrubicin and its synergist | |
| CN1686550A (en) | Anti entity tumour medicinal composition containing dichloro ethamine kind drug | |
| CN1857207A (en) | Slow released compound anticancer injection containing blood vessel inhibitor | |
| CN1850037A (en) | Compound anti-cancer slow-release injected containing blood vessel inhibitor | |
| CN1923284A (en) | Anti-cancer drug slow release injection and uses thereof | |
| CN100340297C (en) | Anticarcinogenic internal implant agent | |
| CN1850050A (en) | Compound anticancer slow-release injection containing vascular inhibitor | |
| CN1686552A (en) | Antientity tumour medicinal composition containing topoenzyme inhibitor | |
| CN100431608C (en) | Anti entity tumour medicinal composition containing tetrazine kind compound | |
| CN101066452A (en) | Solid tumor treating medicine composition containing | |
| CN1286526C (en) | Anti-cancer medicine composition | |
| CN101066451A (en) | Solid tumor treating medicine composition containing dicloethamine | |
| CN100500213C (en) | Anti-tumour medicinal composition containing blood vessel inhibitor | |
| CN1733306A (en) | Anticancer implantation agent containing blood vessel inhibitor and guanine similarities | |
| CN1850041A (en) | Anticancer medicine slow-release preparation containing platinum compound and its synergist |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination |